>PA576483.1 JP 2023040852-A/14: A single-stranded nucleic acids and a composition for inducing -1 frameshift
TAGTGTGG
>PA576482.1 JP 2023040852-A/13: A single-stranded nucleic acids and a composition for inducing -1 frameshift
CCGCATTA
>pdb|8S9I|B Chain B, Crystal structure of the gp32 C-terminal peptide/Dda/dT8
TTTTTTTT
>pdb|8APO|C3 Chain C3, Structure of the mitochondrial ribosome from Polytomella magna with tRNAs bound to the A and P sites
NATGATGT
>pdb|6W7A|B Chain B, The crystal structure of the 2009/H1N1/California PA endonuclease mutant E119D bound to DNA oligomer TAGCAT (uncleaved, 5mM overnight DNA soak)
TTAGCATT
>pdb|8FOH|P Chain P, Cryo-EM structure of S. cerevisiae DNA polymerase alpha-primase complex in the RNA synthesis state
NGGCGGGC
>pdb|8G4G|B Chain B, Crystal Engineering with One 8-mer DNA
ATCGGCCG
>PA573984.1 JP 2023023890-A/16: Double-chained PNA probe
GCGGGCCA
>PA573983.1 JP 2023023890-A/15: Double-chained PNA probe
TCATGCAG
>PA573902.1 JP 2023021634-A/14: A fluorescently labeled nucleic acid probe
NNNNGAAN
>pdb|8CAS|3 Chain 3, Cryo-EM structure of native Otu2-bound ubiquitinated 48S initiation complex (partial)
NAAATGTC
>pdb|8FOG|P Chain P, Crystal structure of human DNA polymerase eta incorporating dITP across dT
AGTGTGAG
>pdb|8FN3|P Chain P, Crystal structure of human DNA polymerase eta incorporating dITP across dC
AGTGTGAG
>pdb|7ZEX|B Chain B, Complex Cyp33-RRMdelta alpha : UAAUGUCG RNA
TAATGTCG
>pdb|1ZDJ|S Chain S, STRUCTURE OF BACTERIOPHAGE COAT PROTEIN-LOOP RNA COMPLEX
GGATCACC
>pdb|1ZDJ|R Chain R, STRUCTURE OF BACTERIOPHAGE COAT PROTEIN-LOOP RNA COMPLEX
GGATCACC
>pdb|8EG4|B Chain B, [iU:Ag+:iU] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
NCANACAG
>pdb|8CX1|L Chain L, Cryo-EM structure of human APOBEC3G/HIV-1 Vif/CBFbeta/ELOB/ELOC dimeric complex in State 1
NAAATATT
>pdb|8CX1|K Chain K, Cryo-EM structure of human APOBEC3G/HIV-1 Vif/CBFbeta/ELOB/ELOC dimeric complex in State 1
NAAATATT
>pdb|8CX0|K Chain K, Cryo-EM structure of human APOBEC3G/HIV-1 Vif/CBFbeta/ELOB/ELOC monomeric complex
NAAAAAAA
>pdb|7SD7|D Chain D, [C:Hg2+:T] Metal-mediated DNA base pair in a self-assembling rhombohedral lattice
TCTGATGT
>PA566189.1 WO 2022270585-A/181: Combination of antisense oligomers
AACAGTGT
>PA566188.1 WO 2022270585-A/180: Combination of antisense oligomers
AAACAGTG
>PA566187.1 WO 2022270585-A/179: Combination of antisense oligomers
TAAACAGT
>PA566186.1 WO 2022270585-A/178: Combination of antisense oligomers
TTAAACAG
>PA566185.1 WO 2022270585-A/177: Combination of antisense oligomers
ATTAAACA
>PA566184.1 WO 2022270585-A/176: Combination of antisense oligomers
GATTAAAC
>PA566183.1 WO 2022270585-A/175: Combination of antisense oligomers
AGATTAAA
>PA566182.1 WO 2022270585-A/174: Combination of antisense oligomers
AAGATTAA
>PA566181.1 WO 2022270585-A/173: Combination of antisense oligomers
AAAGATTA
>PA566180.1 WO 2022270585-A/172: Combination of antisense oligomers
AAAAGATT
>PA566179.1 WO 2022270585-A/171: Combination of antisense oligomers
GAAAAGAT
>PA566178.1 WO 2022270585-A/170: Combination of antisense oligomers
AGAAAAGA
>PA566177.1 WO 2022270585-A/169: Combination of antisense oligomers
GAGAAAAG
>PA566084.1 WO 2022270585-A/76: Combination of antisense oligomers
ACACTGTT
>PA566083.1 WO 2022270585-A/75: Combination of antisense oligomers
CACTGTTT
>PA566082.1 WO 2022270585-A/74: Combination of antisense oligomers
ACTGTTTA
>PA566081.1 WO 2022270585-A/73: Combination of antisense oligomers
CTGTTTAA
>PA566080.1 WO 2022270585-A/72: Combination of antisense oligomers
TGTTTAAT
>PA566079.1 WO 2022270585-A/71: Combination of antisense oligomers
GTTTAATC
>PA566078.1 WO 2022270585-A/70: Combination of antisense oligomers
TTTAATCT
>PA566077.1 WO 2022270585-A/69: Combination of antisense oligomers
TTAATCTT
>PA566076.1 WO 2022270585-A/68: Combination of antisense oligomers
TAATCTTT
>PA566075.1 WO 2022270585-A/67: Combination of antisense oligomers
AATCTTTT
>PA566074.1 WO 2022270585-A/66: Combination of antisense oligomers
ATCTTTTC
>PA566073.1 WO 2022270585-A/65: Combination of antisense oligomers
TCTTTTCT
>PA566072.1 WO 2022270585-A/64: Combination of antisense oligomers
CTTTTCTC
>pdb|7YGA|A Chain A, Cryo-EM structure of Tetrahymena ribozyme conformation 2 undergoing the second-step self-splicing
TCGNAACC
>pdb|7YG9|A Chain A, Cryo-EM structure of Tetrahymena ribozyme conformation 1 undergoing the second-step self-splicing
TCGNAACC
>pdb|118D|A Chain A, CRYSTAL AND MOLECULAR STRUCTURE OF D(GTGCGCAC): INVESTIGATION OF THE EFFECTS OF BASE SEQUENCE ON THE CONFORMATION OF OCTAMER DUPLEXES
GTGCGCAC
>pdb|1D79|A Chain A, HIGH RESOLUTION REFINEMENT OF THE HEXAGONAL A-DNA OCTAMER D(GTGTACAC) AT 1.4 ANGSTROMS RESOLUTION
GTGTACAC
>pdb|1D78|A Chain A, HIGH RESOLUTION REFINEMENT OF THE HEXAGONAL A-DNA OCTAMER D(GTGTACAC) AT 1.4 ANGSTROMS RESOLUTION
GTGTACAC
>pdb|8E8A|P Chain P, Human DNA polymerase eta-DNA-dT-ended primer binary complex
AGCGTCAT
>PA564023.1 JP 2022544004-A/44: ENGINEERED NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USES THEREOF
TCATTCTA
>pdb|8DAG|D Chain D, [8 bp center] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
TCTGATGT
>pdb|8DAG|B Chain B, [8 bp center] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
NCGTCACA
>pdb|8CYN|D Chain D, [2T7+20bp Linker] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle with 20 bp Sticky-End Linker
TCTGATGT
>pdb|8CYM|D Chain D, [2T7+9bp Linker] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle with 9 bp Sticky-End Linker
TCTGATGT
>pdb|8CS2|D Chain D, [(1AP)G/TC] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
TCTGATGT
>pdb|8CS1|D Chain D, [GA/CT] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
CTTGATGT
>pdb|8CS8|D Chain D, [High G:C, High Vapor Diffusion] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
TCCTCTGT
>PE006835.1 KR 1020220080012-A/2943: USING TRUNCATED GUIDE RNAS (TRU-GRNAS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING
ACAAGATG
>PE006654.1 KR 1020220080012-A/2762: USING TRUNCATED GUIDE RNAS (TRU-GRNAS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING
TAGCTGTT
>pdb|8D31|C Chain C, [AG/TC] Self-Assembled 3D DNA Cubic Tensegrity Triangle with 24 bp Arm Length
NGCTAGGC
>pdb|8D31|G Chain G, [AG/TC] Self-Assembled 3D DNA Cubic Tensegrity Triangle with 24 bp Arm Length
NGCTAAGC
>OF490587.1 KR 1020220070324-A/254: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
ACTCGCCA
>OF490534.1 KR 1020220070324-A/201: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
ACTCGCCA
>OF405770.1 KR 1020220035338-A/3: ENHANCING PRODUCTION OF LENTIVIRAL VECTORS
TGGTRAGT
>OF490630.1 KR 1020220070324-A/297: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
ACTCGCCA
>OF448049.1 KR 1020220024954-A/3: METHOD FOR THE PRODUCTION OF AN ANTIBODY
AGGTAAGT
>OF448048.1 KR 1020220024954-A/2: METHOD FOR THE PRODUCTION OF AN ANTIBODY
AGGTRAGT
>OF403881.1 KR 1020220024160-A/2: COMPOSITIONS AND METHODS FOR PREPARING AN ALZHEIMER'S DISEASE ANIMAL MODEL USING MICRORNA
TCATACAC
>OF403880.1 KR 1020220024160-A/1: COMPOSITIONS AND METHODS FOR PREPARING AN ALZHEIMER'S DISEASE ANIMAL MODEL USING MICRORNA
GTCATACA
>OF441366.1 KR 1020220024636-A/32: METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELL BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION
TAATACCA
>OF441365.1 KR 1020220024636-A/31: METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELL BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION
AGAAACCA
>OF441364.1 KR 1020220024636-A/30: METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELL BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION
AAGTATCC
>OF441363.1 KR 1020220024636-A/29: METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELL BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION
ATGTGTAC
>OF441362.1 KR 1020220024636-A/28: METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELL BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION
ATGTATAC
>OF441361.1 KR 1020220024636-A/27: METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELL BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION
TACCTTTC
>OF441360.1 KR 1020220024636-A/26: METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELL BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION
GCATACAT
>OF441359.1 KR 1020220024636-A/25: METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELL BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION
AAGTCTCC
>OF441358.1 KR 1020220024636-A/24: METHOD FOR THE GENERATION OF A MULTIVALENT, MULTISPECIFIC ANTIBODY EXPRESSING CELL BY TARGETED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION
ATGTATGC
>OF441188.1 KR 1020220020378-A/51: PHARMACEUTICAL COMPOSITIONS, KITS AND METHODS FOR TREATING TUMORS
GGACGGAG
>OF481576.1 KR 1020220053048-A/78: Antisense nucleic acids
TGGAGTTC
>OF481268.1 KR 1020220087441-A/8: IMMUNOTHERAPY COMPOUNDS AND METHODS
CCATGGAG
>OF439622.1 KR 1020220024527-A/34: SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
CTGTTTAC
>OF391377.1 KR 1020220010024-A/24: METHOD FOR THE GENERATION OF A PROTEIN EXPRESSING CELL BY TARGETED INTEGRATION USING CRE MRNA
TAATACCA
>OF391376.1 KR 1020220010024-A/23: METHOD FOR THE GENERATION OF A PROTEIN EXPRESSING CELL BY TARGETED INTEGRATION USING CRE MRNA
AGAAACCA
>OF391375.1 KR 1020220010024-A/22: METHOD FOR THE GENERATION OF A PROTEIN EXPRESSING CELL BY TARGETED INTEGRATION USING CRE MRNA
AAGTATCC
>OF391374.1 KR 1020220010024-A/21: METHOD FOR THE GENERATION OF A PROTEIN EXPRESSING CELL BY TARGETED INTEGRATION USING CRE MRNA
ATGTGTAC
>OF391373.1 KR 1020220010024-A/20: METHOD FOR THE GENERATION OF A PROTEIN EXPRESSING CELL BY TARGETED INTEGRATION USING CRE MRNA
ATGTATAC
>OF391372.1 KR 1020220010024-A/19: METHOD FOR THE GENERATION OF A PROTEIN EXPRESSING CELL BY TARGETED INTEGRATION USING CRE MRNA
TACCTTTC
>OF391371.1 KR 1020220010024-A/18: METHOD FOR THE GENERATION OF A PROTEIN EXPRESSING CELL BY TARGETED INTEGRATION USING CRE MRNA
GCATACAT
>OF391370.1 KR 1020220010024-A/17: METHOD FOR THE GENERATION OF A PROTEIN EXPRESSING CELL BY TARGETED INTEGRATION USING CRE MRNA
AAGTCTCC
>OF391369.1 KR 1020220010024-A/16: METHOD FOR THE GENERATION OF A PROTEIN EXPRESSING CELL BY TARGETED INTEGRATION USING CRE MRNA
ATGTATGC
>OF474647.1 KR 1020220047892-A/570: Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
GGCGCGCC
>OF389894.1 KR 1020220012266-A/15: GENE THERAPY VECTORS FOR INFANTILE MALIGNANT OSTEOPETROSIS
AGNNATGN
>OF386469.1 KR 1020220004708-A/13: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-33 ANTAGONIST
CTGCTTCC
>OF380342.1 KR 1020220002910-A/23: TRIPLE HELIX TERMINATOR FOR EFFICIENT RNA TRANS-SPLICING
TTTCTTTT
>OF379430.1 KR 1020220010471-A/30: ELECTROCHEMILUMINESCENT LABELED PROBES FOR USE IN IMMUNOASSAY METHODS, METHODS USING SUCH AND KITS COMPRISING SAME
AAGCGTCT
>OF463891.1 KR 1020220038549-A/150: MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODING
CACTCAGT
>OF463890.1 KR 1020220038549-A/149: MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODING
ACTGAGTG
>OF463508.1 KR 1020220047623-A/13: COMPOSITIONS AND METHODS FOR IDENTIFYING REGULATORS OF CELL TYPE FATE SPECIFICATION
NNNNGNNN
>OF463507.1 KR 1020220047623-A/12: COMPOSITIONS AND METHODS FOR IDENTIFYING REGULATORS OF CELL TYPE FATE SPECIFICATION
NNNNGATT
>OF378461.1 KR 1020220042046-A/22: USE OF MIR-204 INHIBITOR TO INCREASE NURR1 PROTEIN EXPRESSION
AACAATAC
>OF378460.1 KR 1020220042046-A/21: USE OF MIR-204 INHIBITOR TO INCREASE NURR1 PROTEIN EXPRESSION
AACAATAC
>OF378451.1 KR 1020220042046-A/12: USE OF MIR-204 INHIBITOR TO INCREASE NURR1 PROTEIN EXPRESSION
CAGAATAC
>OF378450.1 KR 1020220042046-A/11: USE OF MIR-204 INHIBITOR TO INCREASE NURR1 PROTEIN EXPRESSION
CAGAATAC
>OF378449.1 KR 1020220042046-A/10: USE OF MIR-204 INHIBITOR TO INCREASE NURR1 PROTEIN EXPRESSION
GTATTCTG
>OF378448.1 KR 1020220042046-A/9: USE OF MIR-204 INHIBITOR TO INCREASE NURR1 PROTEIN EXPRESSION
GTATTCTG
>OF376152.1 KR 1020220059418-A/15: Microparticle probe for nucleic acid separation and detection for multiplexed diagnosis
TTATTATT
>OF374364.1 KR 1020220040983-A/22: Prime editing-based gene editing composition with improved editing efficiency and use thereof
ACGGAGCC
>OF374346.1 KR 1020220040983-A/4: Prime editing-based gene editing composition with improved editing efficiency and use thereof
ATGGAGCC
>OF454216.1 KR 1020220038399-A/73: COMPOSITION AND METHOD FOR ADOPTIVE IMMUNOTHERAPY
GCGGCCGC
>OF492605.1 KR 1020220082047-A/16: VECTOR FOR CANCER TREATMENT
ACAAGTTT
>OF363868.1 KR 1020220025587-A/9: Helix 73-derived RNA molecules interacting with Erm protein and methods of use thereof
AGGACGGA
>OF363867.1 KR 1020220025587-A/8: Helix 73-derived RNA molecules interacting with Erm protein and methods of use thereof
CCCGCCAC
>OF492372.1 KR 1020220082033-A/8: PRODUCER VIRUSES FOR GENERATION OF RETROVIRUSES IN SITU
ATTTTTAT
>pdb|8DWM|G Chain G, Host-guest complex of bleomycin A2 fully bound to CTTAGTTATAACTAAG
NAACTAAG
>pdb|8DWM|B Chain B, Host-guest complex of bleomycin A2 fully bound to CTTAGTTATAACTAAG
CTTAGTTA
>pdb|8DW8|G Chain G, Host-guest structure of BLMA2 partially bound to 5'-ATTAGTTATAACTAAT-3'
NAACTAAT
>pdb|8DW8|B Chain B, Host-guest structure of BLMA2 partially bound to 5'-ATTAGTTATAACTAAT-3'
ATTAGTTA
>pdb|8DW1|G Chain G, Crystal structure of a host-guest complex with 5'-CTTAGTTATAACTAAG-3'
NAACTAAG
>pdb|8DW1|D Chain D, Crystal structure of a host-guest complex with 5'-CTTAGTTATAACTAAG-3'
CTTAGTTA
>pdb|7U3S|C Chain C, [2T7+21] Self-assembling tensegrity triangle with two turns of DNA and the sticky end addition of a two-turn linker per axis with R3 symmetry
NCTGATGT
>pdb|7U3R|C Chain C, [2T7+10] Self-assembling tensegrity triangle with two turns of DNA and the sticky end attachment of a one-turn linker per axis, with R3 symmetry
TCTGATGT
>pdb|316D|B Chain B, Selectivity of F8-actinomycin D for RNA:DNA hybrids and its anti-leukemia activity
GAAGCTTC
>pdb|316D|A Chain A, Selectivity of F8-actinomycin D for RNA:DNA hybrids and its anti-leukemia activity
GAAGCTTC
>pdb|5GXH|B Chain B, The structure of the Gemin5 WD40 domain with AAUUUUUG
AATTTTTG
>pdb|6WVJ|R Chain R, Cryo-EM structure of Bacillus subtilis RNA Polymerase elongation complex
NGCGCGCG
>pdb|3JB9|O Chain O, Cryo-EM structure of the yeast spliceosome at 3.6 angstrom resolution
NTATGTAT
>pdb|7Q4L|B Chain B, The solution structure of hsDND1 RRM12 bound to CUUAUUUG RNA
CTTATTTG
>pdb|7VKL|B Chain B, Crystal structure of MmIMP3-KH12 in complex with zipcode RNA
ACGGACTC
>pdb|7TR9|T Chain T, Cascade complex from type I-A CRISPR-Cas system
NACCCAGT
>pdb|6M6R|B Chain B, Crystal structure of Caenorhabditis elegans Dicer-related helicase 3 (DRH-3) C-terminal domain with 5'-ppp 8-mer ssRNA
NGCCGCCC
>pdb|7X5L|C Chain C, Tir-dsDNA complex, the initial binding state
TTAATTAA
>pdb|7X5L|A Chain A, Tir-dsDNA complex, the initial binding state
ATAAATTA
>pdb|7JSC|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J31 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JSB|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J30 immobile Holliday junction with R3 symmetry
TCGAGTCC
>pdb|7JS2|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J36 immobile Holliday junction with R3 symmetry
TCTGAGTG
>pdb|7JS1|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J33 immobile Holliday junction with R3 symmetry
TCTGAGTC
>pdb|7JS0|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J31 immobile Holliday junction with R3 symmetry
TCTGAGTG
>pdb|7JRZ|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J5 immobile Holliday junction with R3 symmetry
TCTGAGTC
>pdb|7JRY|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J4 immobile Holliday junction with R3 symmetry
TCTGAGTC
>pdb|7JPC|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J7 immobile Holliday junction
TCTGAGTA
>pdb|7JPB|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J2 immobile Holliday junction
TCTGAGTC
>pdb|7JPA|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J5 immobile Holliday junction
TCTGAGTC
>pdb|7JP9|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J8 immobile Holliday junction
TCTGAGTG
>pdb|7JP8|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J10 immobile Holliday junction
TCTGAGTT
>pdb|7JP7|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J16 immobile Holliday junction
TCTGAGTG
>pdb|7JP6|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J20 immobile Holliday junction
TCTGAGTC
>pdb|7JP5|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J22 immobile Holliday junction
TCTGAGTG
>pdb|7JON|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J23 immobile Holliday junction
TCTGAGTG
>pdb|7JOL|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J24 immobile Holliday junction
TCTGAGTG
>pdb|7JOK|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J26 immobile Holliday junction
TCTGAGTG
>pdb|7JOJ|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J28 immobile Holliday junction
TCTGAGTG
>pdb|7JOI|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J30 immobile Holliday junction
TCTGAGTC
>pdb|7JOH|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J31 immobile Holliday junction
TCTGAGTG
>pdb|7JOG|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 duplex version) containing the J33 immobile Holliday junction
TCTGAGTC
>pdb|7JNM|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J36 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JNL|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J34 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JNK|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J33 immobile Holliday junction with R3 symmetry
TCGAGTCC
>pdb|7JNJ|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J26 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JLF|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J24 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JLE|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J23 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JLD|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J22 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JLC|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J21 immobile Holliday junction with R3 symmetry
TCGAGTCC
>pdb|7JLB|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J19 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JLA|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J16 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JL9|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J14 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JKK|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J10 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JKJ|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J8 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JKI|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J7 immobile Holliday junction with R3 symmetry
TCGAGTCA
>pdb|7JKH|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J5 immobile Holliday junction with R3 symmetry
TCGAGTCC
>pdb|7JKG|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J3 immobile Holliday junction with R3 symmetry
TCGAGTCG
>pdb|7JKE|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J2 immobile Holliday junction
TCGAGTCC
>pdb|7JKD|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x6 scramble duplex version) containing the J1 immobile Holliday junction
TCGAGTCT
>pdb|7S3C|B Chain B, Crystal structure of intact U2AF65 RRM-region bound to AdML-A5 oligonucleotide
NTNATNCC
>pdb|7S3B|B Chain B, Crystal structure of intact U2AF65 RRM-region bound to AdML-G5 oligonucleotide
NTNGTNCC
>pdb|7S3A|B Chain B, Crystal structure of intact U2AF65 RRM-region bound to AdML-C5 oligonucleotide
NTNCTNCC
>pdb|5V2H|D Chain D, RNA octamer containing glycol nucleic acid, SgnT
NGAANTCG
>pdb|5V2H|C Chain C, RNA octamer containing glycol nucleic acid, SgnT
NGAANTCG
>pdb|5V2H|B Chain B, RNA octamer containing glycol nucleic acid, SgnT
NGAANTCG
>pdb|5V2H|A Chain A, RNA octamer containing glycol nucleic acid, SgnT
NGAANTCG
>pdb|4M94|G Chain G, d(ATCCGTTATAACGGAT) complexed with Moloney Murine Leukemia virus reverse transcriptase catalytic fragment
NAACGGAT
>pdb|4M94|B Chain B, d(ATCCGTTATAACGGAT) complexed with Moloney Murine Leukemia virus reverse transcriptase catalytic fragment
ATCCGNTA
>pdb|7R96|D Chain D, Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
TCTGATGT
>OF334376.1 KR 1020210122801-A/40: LIVER-SPECIFIC INDUCIBLE PROMOTERS AND METHODS OF USE THEREOF
GATCGATC
>OF330302.1 KR 1020210133215-A/65: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
TTTGGTCC
>OF330301.1 KR 1020210133215-A/64: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
AACGGTTA
>OF330300.1 KR 1020210133215-A/63: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
TGTTTCGG
>OF330299.1 KR 1020210133215-A/62: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
CTGCTGAA
>OF330298.1 KR 1020210133215-A/61: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
GGCAAGAC
>OF330287.1 KR 1020210133215-A/50: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
AAGCGATC
>OF330286.1 KR 1020210133215-A/49: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
TACCTGAT
>OF330285.1 KR 1020210133215-A/48: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
TGGTGTTG
>OF330284.1 KR 1020210133215-A/47: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
ATATGCTT
>OF330283.1 KR 1020210133215-A/46: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
TCCCTCAA
>OF330252.1 KR 1020210133215-A/15: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
GGCGTTAT
>OF330251.1 KR 1020210133215-A/14: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
TCTCGGAA
>OF330250.1 KR 1020210133215-A/13: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
ACGTGGTA
>OF330249.1 KR 1020210133215-A/12: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
AAAATGCG
>OF330248.1 KR 1020210133215-A/11: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
AGCTCCAG
>OF327821.1 KR 1020210125999-A/22: GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE
AGNNATGN
>OF314923.1 KR 1020210091180-A/10506: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF314915.1 KR 1020210091180-A/10498: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF314789.1 KR 1020210091180-A/10372: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF314765.1 KR 1020210091180-A/10348: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF314753.1 KR 1020210091180-A/10336: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF314741.1 KR 1020210091180-A/10324: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF314728.1 KR 1020210091180-A/10311: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF314715.1 KR 1020210091180-A/10298: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF314702.1 KR 1020210091180-A/10285: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF314692.1 KR 1020210091180-A/10275: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF314680.1 KR 1020210091180-A/10263: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF314550.1 KR 1020210091180-A/10133: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF314542.1 KR 1020210091180-A/10125: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF314416.1 KR 1020210091180-A/9999: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF314392.1 KR 1020210091180-A/9975: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF314380.1 KR 1020210091180-A/9963: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF314368.1 KR 1020210091180-A/9951: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF314355.1 KR 1020210091180-A/9938: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF314342.1 KR 1020210091180-A/9925: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF314329.1 KR 1020210091180-A/9912: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF314319.1 KR 1020210091180-A/9902: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF314307.1 KR 1020210091180-A/9890: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF314177.1 KR 1020210091180-A/9760: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF314169.1 KR 1020210091180-A/9752: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF314043.1 KR 1020210091180-A/9626: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF314019.1 KR 1020210091180-A/9602: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF314007.1 KR 1020210091180-A/9590: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF313995.1 KR 1020210091180-A/9578: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF313982.1 KR 1020210091180-A/9565: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF313969.1 KR 1020210091180-A/9552: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF313956.1 KR 1020210091180-A/9539: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF313946.1 KR 1020210091180-A/9529: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF313934.1 KR 1020210091180-A/9517: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF313804.1 KR 1020210091180-A/9387: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF313796.1 KR 1020210091180-A/9379: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF313670.1 KR 1020210091180-A/9253: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF313646.1 KR 1020210091180-A/9229: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF313634.1 KR 1020210091180-A/9217: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF313622.1 KR 1020210091180-A/9205: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF313609.1 KR 1020210091180-A/9192: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF313596.1 KR 1020210091180-A/9179: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF313583.1 KR 1020210091180-A/9166: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF313573.1 KR 1020210091180-A/9156: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF313561.1 KR 1020210091180-A/9144: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF313431.1 KR 1020210091180-A/9014: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF313423.1 KR 1020210091180-A/9006: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF313297.1 KR 1020210091180-A/8880: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF313273.1 KR 1020210091180-A/8856: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF313261.1 KR 1020210091180-A/8844: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF313249.1 KR 1020210091180-A/8832: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF313236.1 KR 1020210091180-A/8819: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF313223.1 KR 1020210091180-A/8806: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF313210.1 KR 1020210091180-A/8793: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF313200.1 KR 1020210091180-A/8783: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF313188.1 KR 1020210091180-A/8771: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF313058.1 KR 1020210091180-A/8641: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF313050.1 KR 1020210091180-A/8633: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF312924.1 KR 1020210091180-A/8507: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF312900.1 KR 1020210091180-A/8483: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF312888.1 KR 1020210091180-A/8471: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF312876.1 KR 1020210091180-A/8459: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF312863.1 KR 1020210091180-A/8446: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF312850.1 KR 1020210091180-A/8433: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF312837.1 KR 1020210091180-A/8420: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF312827.1 KR 1020210091180-A/8410: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF312815.1 KR 1020210091180-A/8398: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF312685.1 KR 1020210091180-A/8268: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF312677.1 KR 1020210091180-A/8260: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF312668.1 KR 1020210091180-A/8251: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF312659.1 KR 1020210091180-A/8242: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF312649.1 KR 1020210091180-A/8232: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF312518.1 KR 1020210091180-A/8101: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF312506.1 KR 1020210091180-A/8089: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF312530.1 KR 1020210091180-A/8113: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF312494.1 KR 1020210091180-A/8077: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF312481.1 KR 1020210091180-A/8064: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF312543.1 KR 1020210091180-A/8126: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF312468.1 KR 1020210091180-A/8051: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF312455.1 KR 1020210091180-A/8038: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF312445.1 KR 1020210091180-A/8028: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF312433.1 KR 1020210091180-A/8016: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF312303.1 KR 1020210091180-A/7886: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF312295.1 KR 1020210091180-A/7878: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF312286.1 KR 1020210091180-A/7869: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF312277.1 KR 1020210091180-A/7860: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF312267.1 KR 1020210091180-A/7850: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF312161.1 KR 1020210091180-A/7744: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF312148.1 KR 1020210091180-A/7731: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF312136.1 KR 1020210091180-A/7719: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF312124.1 KR 1020210091180-A/7707: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF312112.1 KR 1020210091180-A/7695: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF312099.1 KR 1020210091180-A/7682: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF312086.1 KR 1020210091180-A/7669: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF312073.1 KR 1020210091180-A/7656: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF312063.1 KR 1020210091180-A/7646: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF312051.1 KR 1020210091180-A/7634: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF311921.1 KR 1020210091180-A/7504: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF311913.1 KR 1020210091180-A/7496: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF311904.1 KR 1020210091180-A/7487: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF311895.1 KR 1020210091180-A/7478: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF311885.1 KR 1020210091180-A/7468: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF311779.1 KR 1020210091180-A/7362: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF311766.1 KR 1020210091180-A/7349: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF311754.1 KR 1020210091180-A/7337: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF311742.1 KR 1020210091180-A/7325: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF311730.1 KR 1020210091180-A/7313: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF311717.1 KR 1020210091180-A/7300: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF311704.1 KR 1020210091180-A/7287: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF311691.1 KR 1020210091180-A/7274: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF311681.1 KR 1020210091180-A/7264: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF311669.1 KR 1020210091180-A/7252: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF311539.1 KR 1020210091180-A/7122: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF311531.1 KR 1020210091180-A/7114: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF311522.1 KR 1020210091180-A/7105: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF311513.1 KR 1020210091180-A/7096: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF311503.1 KR 1020210091180-A/7086: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF311309.1 KR 1020210091180-A/6892: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF311299.1 KR 1020210091180-A/6882: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF311287.1 KR 1020210091180-A/6870: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF311397.1 KR 1020210091180-A/6980: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF311384.1 KR 1020210091180-A/6967: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF311372.1 KR 1020210091180-A/6955: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF311360.1 KR 1020210091180-A/6943: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF311348.1 KR 1020210091180-A/6931: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF311335.1 KR 1020210091180-A/6918: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF311322.1 KR 1020210091180-A/6905: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF311157.1 KR 1020210091180-A/6740: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF311149.1 KR 1020210091180-A/6732: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF311140.1 KR 1020210091180-A/6723: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF311131.1 KR 1020210091180-A/6714: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF311121.1 KR 1020210091180-A/6704: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF311015.1 KR 1020210091180-A/6598: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF311002.1 KR 1020210091180-A/6585: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF310990.1 KR 1020210091180-A/6573: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF310978.1 KR 1020210091180-A/6561: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF310966.1 KR 1020210091180-A/6549: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF310953.1 KR 1020210091180-A/6536: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF310940.1 KR 1020210091180-A/6523: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF310927.1 KR 1020210091180-A/6510: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF310917.1 KR 1020210091180-A/6500: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF310905.1 KR 1020210091180-A/6488: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF310775.1 KR 1020210091180-A/6358: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF310767.1 KR 1020210091180-A/6350: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF310758.1 KR 1020210091180-A/6341: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF310749.1 KR 1020210091180-A/6332: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF310739.1 KR 1020210091180-A/6322: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF310633.1 KR 1020210091180-A/6216: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF310620.1 KR 1020210091180-A/6203: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF310608.1 KR 1020210091180-A/6191: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF310596.1 KR 1020210091180-A/6179: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF310584.1 KR 1020210091180-A/6167: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF310571.1 KR 1020210091180-A/6154: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF310558.1 KR 1020210091180-A/6141: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF310545.1 KR 1020210091180-A/6128: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF310535.1 KR 1020210091180-A/6118: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF310523.1 KR 1020210091180-A/6106: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF310393.1 KR 1020210091180-A/5976: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF310385.1 KR 1020210091180-A/5968: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF310342.1 KR 1020210091180-A/5925: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF310257.1 KR 1020210091180-A/5840: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF310233.1 KR 1020210091180-A/5816: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF310221.1 KR 1020210091180-A/5804: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF310209.1 KR 1020210091180-A/5792: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF310196.1 KR 1020210091180-A/5779: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF310183.1 KR 1020210091180-A/5766: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF310170.1 KR 1020210091180-A/5753: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF310160.1 KR 1020210091180-A/5743: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF310018.1 KR 1020210091180-A/5601: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF310010.1 KR 1020210091180-A/5593: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF309967.1 KR 1020210091180-A/5550: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF310148.1 KR 1020210091180-A/5731: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF309882.1 KR 1020210091180-A/5465: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF309858.1 KR 1020210091180-A/5441: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF309846.1 KR 1020210091180-A/5429: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF309834.1 KR 1020210091180-A/5417: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF309821.1 KR 1020210091180-A/5404: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF309808.1 KR 1020210091180-A/5391: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF309795.1 KR 1020210091180-A/5378: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF309785.1 KR 1020210091180-A/5368: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF309773.1 KR 1020210091180-A/5356: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF309643.1 KR 1020210091180-A/5226: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF309635.1 KR 1020210091180-A/5218: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF309592.1 KR 1020210091180-A/5175: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF309507.1 KR 1020210091180-A/5090: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF309483.1 KR 1020210091180-A/5066: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF309471.1 KR 1020210091180-A/5054: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF309459.1 KR 1020210091180-A/5042: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF309446.1 KR 1020210091180-A/5029: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF309433.1 KR 1020210091180-A/5016: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF309420.1 KR 1020210091180-A/5003: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF309410.1 KR 1020210091180-A/4993: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF309398.1 KR 1020210091180-A/4981: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF309268.1 KR 1020210091180-A/4851: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF309260.1 KR 1020210091180-A/4843: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF309217.1 KR 1020210091180-A/4800: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF309108.1 KR 1020210091180-A/4691: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF309096.1 KR 1020210091180-A/4679: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF309084.1 KR 1020210091180-A/4667: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF309071.1 KR 1020210091180-A/4654: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF309058.1 KR 1020210091180-A/4641: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF309045.1 KR 1020210091180-A/4628: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF309035.1 KR 1020210091180-A/4618: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF309023.1 KR 1020210091180-A/4606: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF309132.1 KR 1020210091180-A/4715: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF308893.1 KR 1020210091180-A/4476: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF308885.1 KR 1020210091180-A/4468: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF308842.1 KR 1020210091180-A/4425: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF349063.1 KR 1020210142666-A/32: HIGH-AFFINITY TCR FOR RECOGNIZING AFP ANTIGEN
GCGGCCGC
>OF308757.1 KR 1020210091180-A/4340: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF308733.1 KR 1020210091180-A/4316: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF308721.1 KR 1020210091180-A/4304: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF308709.1 KR 1020210091180-A/4292: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF308696.1 KR 1020210091180-A/4279: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF308683.1 KR 1020210091180-A/4266: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF308670.1 KR 1020210091180-A/4253: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF308660.1 KR 1020210091180-A/4243: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF308648.1 KR 1020210091180-A/4231: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF308518.1 KR 1020210091180-A/4101: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF308510.1 KR 1020210091180-A/4093: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF308467.1 KR 1020210091180-A/4050: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF308382.1 KR 1020210091180-A/3965: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF308358.1 KR 1020210091180-A/3941: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF308346.1 KR 1020210091180-A/3929: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF308334.1 KR 1020210091180-A/3917: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF348797.1 KR 1020210122917-A/8: CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES
TTTGAATT
>OF308321.1 KR 1020210091180-A/3904: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF308308.1 KR 1020210091180-A/3891: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF308295.1 KR 1020210091180-A/3878: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF308285.1 KR 1020210091180-A/3868: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF308273.1 KR 1020210091180-A/3856: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF308143.1 KR 1020210091180-A/3726: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF308135.1 KR 1020210091180-A/3718: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF307923.1 KR 1020210091180-A/3506: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF307910.1 KR 1020210091180-A/3493: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF307900.1 KR 1020210091180-A/3483: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF307888.1 KR 1020210091180-A/3471: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF308126.1 KR 1020210091180-A/3709: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF308117.1 KR 1020210091180-A/3700: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF308107.1 KR 1020210091180-A/3690: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF308096.1 KR 1020210091180-A/3679: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGA
>OF308083.1 KR 1020210091180-A/3666: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF307758.1 KR 1020210091180-A/3341: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF307750.1 KR 1020210091180-A/3333: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF307741.1 KR 1020210091180-A/3324: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF307998.1 KR 1020210091180-A/3581: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF307985.1 KR 1020210091180-A/3568: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF307973.1 KR 1020210091180-A/3556: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF307961.1 KR 1020210091180-A/3544: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF307949.1 KR 1020210091180-A/3532: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF307936.1 KR 1020210091180-A/3519: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF307732.1 KR 1020210091180-A/3315: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF307722.1 KR 1020210091180-A/3305: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF307711.1 KR 1020210091180-A/3294: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGA
>OF307698.1 KR 1020210091180-A/3281: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF307613.1 KR 1020210091180-A/3196: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF307600.1 KR 1020210091180-A/3183: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF307588.1 KR 1020210091180-A/3171: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF307576.1 KR 1020210091180-A/3159: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF307564.1 KR 1020210091180-A/3147: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF307551.1 KR 1020210091180-A/3134: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF307538.1 KR 1020210091180-A/3121: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF307525.1 KR 1020210091180-A/3108: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF307515.1 KR 1020210091180-A/3098: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF307503.1 KR 1020210091180-A/3086: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF307337.1 KR 1020210091180-A/2920: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF307326.1 KR 1020210091180-A/2909: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGA
>OF307313.1 KR 1020210091180-A/2896: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF307373.1 KR 1020210091180-A/2956: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF307365.1 KR 1020210091180-A/2948: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF307356.1 KR 1020210091180-A/2939: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF307347.1 KR 1020210091180-A/2930: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF307228.1 KR 1020210091180-A/2811: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF307215.1 KR 1020210091180-A/2798: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF307203.1 KR 1020210091180-A/2786: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF307191.1 KR 1020210091180-A/2774: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF307179.1 KR 1020210091180-A/2762: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF307166.1 KR 1020210091180-A/2749: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF307153.1 KR 1020210091180-A/2736: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF307140.1 KR 1020210091180-A/2723: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF307130.1 KR 1020210091180-A/2713: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF307118.1 KR 1020210091180-A/2701: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF306988.1 KR 1020210091180-A/2571: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF306980.1 KR 1020210091180-A/2563: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF306971.1 KR 1020210091180-A/2554: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF306962.1 KR 1020210091180-A/2545: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF306952.1 KR 1020210091180-A/2535: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF306941.1 KR 1020210091180-A/2524: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGA
>OF306928.1 KR 1020210091180-A/2511: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF306843.1 KR 1020210091180-A/2426: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF306733.1 KR 1020210091180-A/2316: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF306830.1 KR 1020210091180-A/2413: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF306818.1 KR 1020210091180-A/2401: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF306806.1 KR 1020210091180-A/2389: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF306794.1 KR 1020210091180-A/2377: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF306781.1 KR 1020210091180-A/2364: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF306768.1 KR 1020210091180-A/2351: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF306755.1 KR 1020210091180-A/2338: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF306745.1 KR 1020210091180-A/2328: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF306543.1 KR 1020210091180-A/2126: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF306458.1 KR 1020210091180-A/2041: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF306445.1 KR 1020210091180-A/2028: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF306433.1 KR 1020210091180-A/2016: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF306421.1 KR 1020210091180-A/2004: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF306409.1 KR 1020210091180-A/1992: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF306396.1 KR 1020210091180-A/1979: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF306603.1 KR 1020210091180-A/2186: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF306595.1 KR 1020210091180-A/2178: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF306383.1 KR 1020210091180-A/1966: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF306586.1 KR 1020210091180-A/2169: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF306370.1 KR 1020210091180-A/1953: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF306577.1 KR 1020210091180-A/2160: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF306360.1 KR 1020210091180-A/1943: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF306567.1 KR 1020210091180-A/2150: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF306556.1 KR 1020210091180-A/2139: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGA
>OF306348.1 KR 1020210091180-A/1931: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF306218.1 KR 1020210091180-A/1801: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF306210.1 KR 1020210091180-A/1793: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF306201.1 KR 1020210091180-A/1784: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF306192.1 KR 1020210091180-A/1775: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF306182.1 KR 1020210091180-A/1765: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF306171.1 KR 1020210091180-A/1754: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGA
>OF306158.1 KR 1020210091180-A/1741: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF306073.1 KR 1020210091180-A/1656: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF306060.1 KR 1020210091180-A/1643: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF306048.1 KR 1020210091180-A/1631: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF306036.1 KR 1020210091180-A/1619: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF306024.1 KR 1020210091180-A/1607: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF306011.1 KR 1020210091180-A/1594: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF305998.1 KR 1020210091180-A/1581: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF305985.1 KR 1020210091180-A/1568: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF305975.1 KR 1020210091180-A/1558: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF305963.1 KR 1020210091180-A/1546: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF305833.1 KR 1020210091180-A/1416: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF305825.1 KR 1020210091180-A/1408: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF305699.1 KR 1020210091180-A/1282: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF305675.1 KR 1020210091180-A/1258: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF305663.1 KR 1020210091180-A/1246: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF305651.1 KR 1020210091180-A/1234: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF305638.1 KR 1020210091180-A/1221: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF305460.1 KR 1020210091180-A/1043: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF305452.1 KR 1020210091180-A/1035: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF305443.1 KR 1020210091180-A/1026: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF305434.1 KR 1020210091180-A/1017: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF305424.1 KR 1020210091180-A/1007: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF305625.1 KR 1020210091180-A/1208: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF305612.1 KR 1020210091180-A/1195: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF305602.1 KR 1020210091180-A/1185: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF305590.1 KR 1020210091180-A/1173: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF305318.1 KR 1020210091180-A/901: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF305305.1 KR 1020210091180-A/888: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF305293.1 KR 1020210091180-A/876: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF305281.1 KR 1020210091180-A/864: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF305269.1 KR 1020210091180-A/852: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF305256.1 KR 1020210091180-A/839: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF305243.1 KR 1020210091180-A/826: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF305230.1 KR 1020210091180-A/813: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF305220.1 KR 1020210091180-A/803: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF305208.1 KR 1020210091180-A/791: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF305078.1 KR 1020210091180-A/661: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF305070.1 KR 1020210091180-A/653: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF305027.1 KR 1020210091180-A/610: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF304942.1 KR 1020210091180-A/525: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF304918.1 KR 1020210091180-A/501: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF304906.1 KR 1020210091180-A/489: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF304894.1 KR 1020210091180-A/477: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF304881.1 KR 1020210091180-A/464: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF304868.1 KR 1020210091180-A/451: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF304855.1 KR 1020210091180-A/438: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF304845.1 KR 1020210091180-A/428: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF304833.1 KR 1020210091180-A/416: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF304703.1 KR 1020210091180-A/286: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCA
>OF304695.1 KR 1020210091180-A/278: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGC
>OF304686.1 KR 1020210091180-A/269: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGG
>OF304677.1 KR 1020210091180-A/260: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGAAGATG
>OF304667.1 KR 1020210091180-A/250: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGAT
>OF304656.1 KR 1020210091180-A/239: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGA
>OF304643.1 KR 1020210091180-A/226: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAG
>OF304558.1 KR 1020210091180-A/141: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGT
>OF304545.1 KR 1020210091180-A/128: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTT
>OF304533.1 KR 1020210091180-A/116: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTC
>OF304521.1 KR 1020210091180-A/104: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCT
>OF304509.1 KR 1020210091180-A/92: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTG
>OF304496.1 KR 1020210091180-A/79: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGT
>OF304483.1 KR 1020210091180-A/66: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTC
>OF304470.1 KR 1020210091180-A/53: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAA
>OF304460.1 KR 1020210091180-A/43: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCA
>OF304448.1 KR 1020210091180-A/31: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCC
>OF299739.1 KR 1020210131243-A/16: USE OF DOWNREGULATED MIRNA FOR DIAGNOSIS AND TREATMENT
TGTATGAC
>OF299726.1 KR 1020210131243-A/3: USE OF DOWNREGULATED MIRNA FOR DIAGNOSIS AND TREATMENT
GTGTATGA
>OF299695.1 KR 1020210131242-A/16: USE OF UPREGULATED MIRNA FOR DIAGNOSIS AND TREATMENT
TGTATGAC
>OF299682.1 KR 1020210131242-A/3: USE OF UPREGULATED MIRNA FOR DIAGNOSIS AND TREATMENT
GTGTATGA
>pdb|7U84|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 6.0 mM Mn2+ for 600s
AGCGTCAT
>pdb|7U83|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 3.0 mM Mn2+ for 600s
AGCGTCAT
>pdb|7U82|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 1.0 mM Mn2+ for 600s
AGCGTCAT
>pdb|7U81|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.5 mM Mn2+ for 600s
AGCGTCAT
>pdb|7U80|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.25 mM Mn2+ for 600s
AGCGTCAT
>pdb|7U7Z|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.12 mM Mn2+ for 600s
AGCGTCAT
>pdb|7U7Y|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.06 mM Mn2+ for 600s
AGCGTCAT
>pdb|7U7X|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 2.0 mM Mg2+ for 600s
AGCGTCAT
>pdb|7U7W|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 1.0 mM Mg2+ for 600s
AGCGTCAT
>pdb|7U7V|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.4 mM Mg2+ for 600s
AGCGTCAT
>pdb|7U7U|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.1 mM Mg2+ for 600s
AGCGTCAT
>pdb|7U7T|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.05 mM Mg2+ for 600s
AGCGTCAT
>pdb|7U7S|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex in 0.025 mM Mg2+ for 600s
AGCGTCAT
>pdb|7U7R|P Chain P, Human DNA polymerase eta-DNA-dGMPNPP ternary mismatch complex:no Me2+ soaking
AGCGTCAT
>pdb|7U7E|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 60s
AGCGTCAT
>pdb|7U7D|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 30s
AGCGTCAT
>pdb|7U78|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 80s
AGCGTCAT
>pdb|7U77|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 40s
AGCGTCAT
>pdb|7U75|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 0.5 mM Mn2+ for 1800s then with 10 mM Mn2+ for 90s
AGCGTCAT
>pdb|7U74|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 0.5 mM Mn2+ for 1800s then with 10 mM Mn2+ for 30s
AGCGTCAT
>pdb|7U73|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 0.5 mM Mn2+ for 1800s
AGCGTCAT
>pdb|7U72|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:ground state at pH7.0 (K+ MES) with 1 Ca2+ ion
AGCGTCAT
>pdb|7V4G|F Chain F, Crystal structure of human ALKBH5 in complex with m6A-containing ssRNA
TGGNCTGC
>pdb|7V4G|E Chain E, Crystal structure of human ALKBH5 in complex with m6A-containing ssRNA
TGGNCTGC
>pdb|7V4G|D Chain D, Crystal structure of human ALKBH5 in complex with m6A-containing ssRNA
TGGNCTGC
>pdb|6UU9|333 Chain 333, E. coli mutant sigma-S transcription initiation complex with an 8-nt RNA ("Fresh" mutant crystal soaked with GTP, UTP, CTP, and ddATP for 30 minutes)
NAGTCTGN
>pdb|6J0H|A Chain A, Crystal structure of Actinomycin D- d(TTGGCGAA) complex
NTGGCGAA
>pdb|5L1K|P Chain P, PostInsertion complex of Human DNA Polymerase Eta bypassing an O6-Methyl-2'-deoxyguanosine : dC site
AGCGTCAC
>pdb|5L1J|P Chain P, Crystal Structure of Human DNA Polymerase Eta Inserting dTMPNPP Opposite O6-Methyl-2'-deoxyguanosine
AGCGTCAT
>pdb|2K41|B Chain B, NMR structure of uridine bulged RNA duplex
CAGCCGAC
>pdb|2OJ7|A Chain A, NMR structure of the UGUU tetraloop of Duck Epsilon apical stem loop
NCTGTTGT
>pdb|2HK4|B Chain B, Dimeric solution structure of the cyclic octamer d(CCGTCCGT)
NCGTCCGT
>pdb|2HK4|A Chain A, Dimeric solution structure of the cyclic octamer d(CCGTCCGT)
NCGTCCGT
>pdb|202D|B Chain B, SOLUTION STRUCTURE OF THE MENOGARIL-DNA COMPLEX
GACATGTC
>pdb|202D|A Chain A, SOLUTION STRUCTURE OF THE MENOGARIL-DNA COMPLEX
GACATGTC
>pdb|2KNL|B Chain B, Structure of the trimethylene N2-dG:N2-dG interstrand cross-link in the 5'-GpC-3' sequence context
TCCGCGGA
>pdb|2KNL|A Chain A, Structure of the trimethylene N2-dG:N2-dG interstrand cross-link in the 5'-GpC-3' sequence context
TCCGCGGA
>pdb|7O5B|V Chain V, Cryo-EM structure of a Bacillus subtilis MifM-stalled ribosome-nascent chain complex with (p)ppGpp-SRP bound
NGGAAGAC
>pdb|5L1L|P Chain P, PostInsertion complex of Human DNA Polymerase Eta bypassing an O6-Methyl-2'-deoxyguanosine : dT site
AGCGTCAT
>pdb|2K3Z|B Chain B, NMR structure of adenosine bulged RNA duplex with C:G-A triple
CAGCCGAC
>pdb|8PSH|B Chain B, HIGH RESOLUTION NMR STRUCTURE OF THE STEREOREGULAR (ALL-RP)-PHOSPHOROTHIOATE-DNA/RNA HYBRID D (G*PS*C*PS*G*PS*T*PS*C*PS*A*PS*G*PS*G)R(CCUGACGC), MINIMIZED AVERAGE STRUCTURE
CCTGACGC
>pdb|2KD4|B Chain B, Solution structure and thermodynamics of 2',5' RNA intercalation
GCCGCGGC
>pdb|2KD4|A Chain A, Solution structure and thermodynamics of 2',5' RNA intercalation
GCCGCGGC
>pdb|7WL0|J Chain J, Crystal structure of human ALKBH5 in complex with N-oxalylglycine (NOG) and m6A-containing ssRNA
TGGNCTGC
>pdb|7WL0|H Chain H, Crystal structure of human ALKBH5 in complex with N-oxalylglycine (NOG) and m6A-containing ssRNA
TGGNCTGC
>pdb|7WL0|F Chain F, Crystal structure of human ALKBH5 in complex with N-oxalylglycine (NOG) and m6A-containing ssRNA
TGGNCTGC
>pdb|7WL0|D Chain D, Crystal structure of human ALKBH5 in complex with N-oxalylglycine (NOG) and m6A-containing ssRNA
TGGNCTGC
>pdb|7WL0|B Chain B, Crystal structure of human ALKBH5 in complex with N-oxalylglycine (NOG) and m6A-containing ssRNA
TGGNCTGC
>pdb|7WKV|F Chain F, Crystal structure of human ALKBH5 in complex with 2-oxoglutarate (2OG) and m6A-containing ssRNA
TGGNCTGC
>pdb|7WKV|D Chain D, Crystal structure of human ALKBH5 in complex with 2-oxoglutarate (2OG) and m6A-containing ssRNA
TGGNCTGC
>pdb|7WKV|B Chain B, Crystal structure of human ALKBH5 in complex with 2-oxoglutarate (2OG) and m6A-containing ssRNA
TGGNCTGC
>pdb|5JUM|P Chain P, Crystal Structure of Human DNA Polymerase Eta Inserting dCTP Opposite N-(2'-deoxyguanosin-8- yl)-3-aminobenzanthrone (C8-dG-ABA)
AGCGTCAT
>pdb|2KNK|B Chain B, Structure of the trimethylene N2-dG:N2-dG interstrand cross-link in 5'-CpG-3' sequence context
AGGCGCCT
>pdb|2KNK|A Chain A, Structure of the trimethylene N2-dG:N2-dG interstrand cross-link in 5'-CpG-3' sequence context
AGGCGCCT
>pdb|2K71|A Chain A, Structure and dynamics of a DNA GNRA hairpin solved vy high-sensitivity NMR with two independent converging methods, simulated annealing (DYANA) and mesoscopic molecular modelling (BCE/AMBER)
GCGAAAGC
>pdb|8DRH|B Chain B, HIGH RESOLUTION NMR STRUCTURE OF THE D(GCGTCAGG)R(CCUGACGC) HYBRID, MINIMIZED AVERAGE STRUCTURE
CCTGACGC
>pdb|8DRH|A Chain A, HIGH RESOLUTION NMR STRUCTURE OF THE D(GCGTCAGG)R(CCUGACGC) HYBRID, MINIMIZED AVERAGE STRUCTURE
GCGTCAGG
>pdb|203D|B Chain B, THE SOLUTION STRUCTURES OF PSORALEN MONOADDUCTED AND CROSSLINKED DNA OLIGOMERS BY NMR SPECTROSCOPY AND RESTRAINED MOLECULAR DYNAMICS
GCGTACGC
>pdb|203D|A Chain A, THE SOLUTION STRUCTURES OF PSORALEN MONOADDUCTED AND CROSSLINKED DNA OLIGOMERS BY NMR SPECTROSCOPY AND RESTRAINED MOLECULAR DYNAMICS
GCGTACGC
>pdb|204D|B Chain B, THE SOLUTION STRUCTURES OF PSORALEN MONOADDUCTED AND CROSSLINKED DNA OLIGOMERS BY NMR SPECTROSCOPY AND RESTRAINED MOLECULAR DYNAMICS
GCGTACGC
>pdb|204D|A Chain A, THE SOLUTION STRUCTURES OF PSORALEN MONOADDUCTED AND CROSSLINKED DNA OLIGOMERS BY NMR SPECTROSCOPY AND RESTRAINED MOLECULAR DYNAMICS
GCGTACGC
>pdb|7OUO|BBB Chain BBB, Crystal structure of RNA duplex [UCGUGCGA]2 in complex with Ba2+ cation
TCGTGCGA
>pdb|7OUO|AAA Chain AAA, Crystal structure of RNA duplex [UCGUGCGA]2 in complex with Ba2+ cation
TCGTGCGA
>pdb|6XLW|B Chain B, Crystal structure of U2AF65 bound to AdML splice site sequence
NTNTTNCC
>pdb|6D54|A Chain A, Low Temperature joint X-ray/neutron structure of DNA oligonucleotide d(GTGGCCAC)2 with 2'-SeCH3 modification on Cyt5
GTGGNCAC
>pdb|6D4L|A Chain A, Joint X-ray/neutron structure of DNA oligonucleotide d(GTGGCCAC)2 with 2'-SeCH3 modification on Cyt5
GTGGNCAC
>pdb|1R3X|C Chain C, INTRAMOLECULAR DNA TRIPLEX WITH RNA THIRD STRAND, NMR, 10 STRUCTURES
TCTCTCTT
>pdb|1R3X|A Chain A, INTRAMOLECULAR DNA TRIPLEX WITH RNA THIRD STRAND, NMR, 10 STRUCTURES
AGAGAGAA
>pdb|1QET|B Chain B, TANDEM GU MISMATCHES IN RNA, NMR, 30 STRUCTURES
GGATGTCC
>pdb|1QET|A Chain A, TANDEM GU MISMATCHES IN RNA, NMR, 30 STRUCTURES
GGATGTCC
>pdb|1QES|B Chain B, TANDEM GU MISMATCHES IN RNA, NMR, 30 STRUCTURES
GGAGTTCC
>pdb|1QES|A Chain A, TANDEM GU MISMATCHES IN RNA, NMR, 30 STRUCTURES
GGAGTTCC
>pdb|1R3X|B Chain B, INTRAMOLECULAR DNA TRIPLEX WITH RNA THIRD STRAND, NMR, 10 STRUCTURES
TTCTCTCT
>pdb|1TAN|A Chain A, TANDEM DNA, NMR, MINIMIZED AVERAGE STRUCTURE
NGGAGCTG
>pdb|7VBB|R Chain R, Structure of the post state human RNA Polymerase I Elongation Complex
NGCTGACT
>pdb|1D3X|C Chain C, INTRAMOLECULAR DNA TRIPLEX, NMR, 10 STRUCTURES
TCTCTCTT
>pdb|1D3X|A Chain A, INTRAMOLECULAR DNA TRIPLEX, NMR, 10 STRUCTURES
AGAGAGAA
>pdb|1D42|B Chain B, SOLUTION STRUCTURE OF [D(GTATATAC)]2 VIA RESTRAINED MOLECULAR DYNAMICS SIMULATIONS WITH NUCLEAR MAGNETIC RESONANCE CONSTRAINTS DERIVED FROM RELAXATION MATRIX ANALYSIS OF TWO-DIMENSIONAL NUCLEAR OVERHAUSER EFFECT EXPERIMENTS
GTATATAC
>pdb|1LUH|B Chain B, SOLUTION NMR STRUCTURE OF SELF-COMPLIMENTARY DUPLEX 5'-D(TCCG*CGGA)2 CONTAINING A TRIMETHYLENE CROSSLINK AT THE N2 POSITION OF G*
TCCGCGGA
>pdb|1LUH|A Chain A, SOLUTION NMR STRUCTURE OF SELF-COMPLIMENTARY DUPLEX 5'-D(TCCG*CGGA)2 CONTAINING A TRIMETHYLENE CROSSLINK AT THE N2 POSITION OF G*
TCCGCGGA
>pdb|1D70|A Chain A, SOLUTION STRUCTURE OF A DNA OCTAMER CONTAINING THE PRIBNOW BOX VIA RESTRAINED MOLECULAR DYNAMICS SIMULATION WITH DISTANCE AND TORSION ANGLE CONSTRAINTS DERIVED FROM TWO-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE SPECTRAL FITTING
GTATAATG
>pdb|7EZ2|A Chain A, Holo L-16 ScaI Tetrahymena ribozyme
TCGNAACC
>pdb|1HRY|C Chain C, THE 3D STRUCTURE OF THE HUMAN SRY-DNA COMPLEX SOLVED BY MULTID-DIMENSIONAL HETERONUCLEAR-EDITED AND-FILTERED NMR
GTTTGTGC
>pdb|1HRY|B Chain B, THE 3D STRUCTURE OF THE HUMAN SRY-DNA COMPLEX SOLVED BY MULTID-DIMENSIONAL HETERONUCLEAR-EDITED AND-FILTERED NMR
GCACAAAC
>pdb|1HRZ|C Chain C, THE 3D STRUCTURE OF THE HUMAN SRY-DNA COMPLEX SOLVED BY MULTI-DIMENSIONAL HETERONUCLEAR-EDITED AND-FILTERED NMR
GTTTGTGC
>pdb|1HRZ|B Chain B, THE 3D STRUCTURE OF THE HUMAN SRY-DNA COMPLEX SOLVED BY MULTI-DIMENSIONAL HETERONUCLEAR-EDITED AND-FILTERED NMR
GCACAAAC
>pdb|1HZ2|B Chain B, SOLUTION NMR STRUCTURE OF SELF-COMPLEMENTARY DUPLEX 5'-D(AGGCG*CCT)2 CONTAINING A TRIMETHYLENE CROSSLINK AT THE N2 POSITION OF G*. MODEL OF A MALONDIALDEHYDE CROSSLINK
AGGCGCCT
>pdb|1HZ2|A Chain A, SOLUTION NMR STRUCTURE OF SELF-COMPLEMENTARY DUPLEX 5'-D(AGGCG*CCT)2 CONTAINING A TRIMETHYLENE CROSSLINK AT THE N2 POSITION OF G*. MODEL OF A MALONDIALDEHYDE CROSSLINK
AGGCGCCT
>pdb|1EVO|R Chain R, NMR OBSERVATION OF A NOVEL C-TETRAD
TGGGCGGT
>pdb|1EVO|Q Chain Q, NMR OBSERVATION OF A NOVEL C-TETRAD
TGGGCGGT
>pdb|1EVO|P Chain P, NMR OBSERVATION OF A NOVEL C-TETRAD
TGGGCGGT
>pdb|1EVO|O Chain O, NMR OBSERVATION OF A NOVEL C-TETRAD
TGGGCGGT
>pdb|1EU6|B Chain B, DIMERIC SOLUTION STRUCTURE OF THE CYCLIC OCTAMER CD(CATTCATT)
NATTCATT
>pdb|1EU6|A Chain A, DIMERIC SOLUTION STRUCTURE OF THE CYCLIC OCTAMER CD(CATTCATT)
NATTCATT
>pdb|1EU2|B Chain B, DIMERIC SOLUTION STRUCTURE OF THE CYCLIC OCTAMER CD(TGCTCGCT)
NGCTCGCT
>pdb|1EU2|A Chain A, DIMERIC SOLUTION STRUCTURE OF THE CYCLIC OCTAMER CD(TGCTCGCT)
NGCTCGCT
>pdb|1EJZ|A Chain A, SOLUTION STRUCTURE OF A HNA-RNA HYBRID
CGCTACGC
>pdb|1BYX|A Chain A, CHIMERIC HYBRID DUPLEX R(GCAGUGGC).R(GCCA)D(CTGC) COMPRISING THE TRNA-DNA JUNCTION FORMED DURING INITIATION OF HIV-1 REVERSE TRANSCRIPTION
GCAGTGGC
>pdb|1AL9|B Chain B, NMR STUDY OF DNA (5'-D(*AP*CP*GP*TP*AP*CP*GP*T)-3') SELF-COMPLEMENTARY DUPLEX COMPLEXED WITH A BIS-DAUNORUBICIN, MINIMIZED AVERAGE STRUCTURE
ACGTACGT
>pdb|1AL9|A Chain A, NMR STUDY OF DNA (5'-D(*AP*CP*GP*TP*AP*CP*GP*T)-3') SELF-COMPLEMENTARY DUPLEX COMPLEXED WITH A BIS-DAUNORUBICIN, MINIMIZED AVERAGE STRUCTURE
ACGTACGT
>pdb|124D|B Chain B, STRUCTURE OF A DNA:RNA HYBRID DUPLEX: WHY RNASE H DOES NOT CLEAVE PURE RNA
CATGTGAC
>pdb|108D|B Chain B, THE SOLUTION STRUCTURE OF A DNA COMPLEX WITH THE FLUORESCENT BIS INTERCALATOR TOTO DETERMINED BY NMR SPECTROSCOPY
CGCTAGCG
>pdb|108D|A Chain A, THE SOLUTION STRUCTURE OF A DNA COMPLEX WITH THE FLUORESCENT BIS INTERCALATOR TOTO DETERMINED BY NMR SPECTROSCOPY
CGCTAGCG
>pdb|1NXR|B Chain B, HIV-1 POLYPURINE HYBRID, R(GAGGACUG):D(CAGTCCTC), NMR, 18 STRUCTURES
GAGGACTG
>pdb|1N96|B Chain B, DIMERIC SOLUTION STRUCTURE OF THE CYCLIC OCTAMER CD(CGCTCATT)
NGCTCATT
>pdb|1N96|A Chain A, DIMERIC SOLUTION STRUCTURE OF THE CYCLIC OCTAMER CD(CGCTCATT)
NGCTCATT
>pdb|1N37|B Chain B, NMR Solution Structure of the Anthracycline Respinomycin D Intercalation Complex with a Double Stranded DNA Molecule (AGACGTCT)2
AGACGTCT
>pdb|1N37|A Chain A, NMR Solution Structure of the Anthracycline Respinomycin D Intercalation Complex with a Double Stranded DNA Molecule (AGACGTCT)2
AGACGTCT
>pdb|1KVH|A Chain A, NCSi-gb-bulge-DNA complex induced formation of a DNA bulge structure by a molecular wedge ligand-post-activated neocarzinostatin chromophore
CCCGATGC
>pdb|1K1R|A Chain A, HETERODUPLEX OF CHIRALLY PURE R-METHYLPHOSPHONATE/DNA DUPLEX
TGTTTGGC
>pdb|1K1H|A Chain A, HETERODUPLEX OF CHIRALLY PURE METHYLPHOSPHONATE/DNA DUPLEX
TGTTTGGC
>pdb|1JVC|B Chain B, Dimeric DNA Quadruplex Containing Major Groove-Aligned A.T.A.T and G.C.G.C Tetrads Stabilized by Inter-Subunit Watson-Crick A:T and G:C Pairs
GAGCAGGT
>pdb|1JVC|A Chain A, Dimeric DNA Quadruplex Containing Major Groove-Aligned A.T.A.T and G.C.G.C Tetrads Stabilized by Inter-Subunit Watson-Crick A:T and G:C Pairs
GAGCAGGT
>pdb|1G80|B Chain B, NMR SOLUTION STRUCTURE OF D(GCGTACGC)2
GCGTACGC
>pdb|1G80|A Chain A, NMR SOLUTION STRUCTURE OF D(GCGTACGC)2
GCGTACGC
>pdb|1G7Z|B Chain B, NMR SOLUTION STRUCTURE OF D(CGCTAGCG)2
CGCTAGCG
>pdb|1G7Z|A Chain A, NMR SOLUTION STRUCTURE OF D(CGCTAGCG)2
CGCTAGCG
>pdb|1EKD|B Chain B, NMR AND MOLECULAR MODELING REVEAL THAT DIFFERENT HYDROGEN BONDING PATTERNS ARE POSSIBLE FOR GU PAIRS: ONE HYDROGEN BOND FOR EACH GU PAIR IN R(GGCGUGCC)2 AND TWO FOR EACH GU PAIR IN R(GAGUGCUC)2
GGCGTGCC
>pdb|1EKD|A Chain A, NMR AND MOLECULAR MODELING REVEAL THAT DIFFERENT HYDROGEN BONDING PATTERNS ARE POSSIBLE FOR GU PAIRS: ONE HYDROGEN BOND FOR EACH GU PAIR IN R(GGCGUGCC)2 AND TWO FOR EACH GU PAIR IN R(GAGUGCUC)2
GGCGTGCC
>pdb|1EKA|B Chain B, NMR AND MOLECULAR MODELING REVEAL THAT DIFFERENT HYDROGEN BONDING PATTERNS ARE POSSIBLE FOR GU PAIRS: ONE HYDROGEN BOND FOR EACH GU PAIR IN R(GGCGUGCC)2 AND TWO FOR EACH GU PAIR IN R(GAGUGCUC)2
GAGTGCTC
>pdb|1EKA|A Chain A, NMR AND MOLECULAR MODELING REVEAL THAT DIFFERENT HYDROGEN BONDING PATTERNS ARE POSSIBLE FOR GU PAIRS: ONE HYDROGEN BOND FOR EACH GU PAIR IN R(GGCGUGCC)2 AND TWO FOR EACH GU PAIR IN R(GAGUGCUC)2
GAGTGCTC
>pdb|1GUC|B Chain B, SOLUTION NMR STRUCTURE OF AN RNA WITH TANDEM, SYMMETRIC GU MISMATCHES, 30 STRUCTURES
GAGGTCTC
>pdb|1GUC|A Chain A, SOLUTION NMR STRUCTURE OF AN RNA WITH TANDEM, SYMMETRIC GU MISMATCHES, 30 STRUCTURES
GAGGTCTC
>pdb|1MWG|B Chain B, STRUCTURE OF RIBONUCLEIC ACID, NMR, MINIMIZED AVERAGE STRUCTURE
GGCAGGCC
>pdb|1MWG|A Chain A, STRUCTURE OF RIBONUCLEIC ACID, NMR, MINIMIZED AVERAGE STRUCTURE
GGCAGGCC
>pdb|1MIS|B Chain B, STRUCTURE OF RNA (5'-R(GP*CP*GP*GP*AP*CP*GP*C)-3') ANTI-PARALLEL RNA DUPLEX WITH TANDEM G:A MISMATCHES, NMR, MINIMIZED AVERAGE STRUCTURE
GCGGACGC
>pdb|1MIS|A Chain A, STRUCTURE OF RNA (5'-R(GP*CP*GP*GP*AP*CP*GP*C)-3') ANTI-PARALLEL RNA DUPLEX WITH TANDEM G:A MISMATCHES, NMR, MINIMIZED AVERAGE STRUCTURE
GCGGACGC
>pdb|1D3X|B Chain B, INTRAMOLECULAR DNA TRIPLEX, NMR, 10 STRUCTURES
TTCTCTCT
>pdb|1AU6|B Chain B, SOLUTION STRUCTURE OF DNA D(CATGCATG) INTERSTRAND-CROSSLINKED BY BISPLATIN COMPOUND (1,1/T,T), NMR, MINIMIZED AVERAGE STRUCTURE
CATGCATG
>pdb|1AU6|A Chain A, SOLUTION STRUCTURE OF DNA D(CATGCATG) INTERSTRAND-CROSSLINKED BY BISPLATIN COMPOUND (1,1/T,T), NMR, MINIMIZED AVERAGE STRUCTURE
CATGCATG
>pdb|1ESS|A Chain A, STEROID TETHERED DNA, NMR, MINIMIZED AVERAGE STRUCTURE
NGGAGCTG
>pdb|1NXR|A Chain A, HIV-1 POLYPURINE HYBRID, R(GAGGACUG):D(CAGTCCTC), NMR, 18 STRUCTURES
CAGTCCTC
>pdb|1GTC|A Chain A, HUMAN IMMUNODEFICIENCY VIRUS-1 OKAZAKI FRAGMENT, DNA-RNA CHIMERA, NMR, 11 STRUCTURES
GCAGTGGC
>pdb|124D|A Chain A, STRUCTURE OF A DNA:RNA HYBRID DUPLEX: WHY RNASE H DOES NOT CLEAVE PURE RNA
GTCACATG
>pdb|1D70|B Chain B, SOLUTION STRUCTURE OF A DNA OCTAMER CONTAINING THE PRIBNOW BOX VIA RESTRAINED MOLECULAR DYNAMICS SIMULATION WITH DISTANCE AND TORSION ANGLE CONSTRAINTS DERIVED FROM TWO-DIMENSIONAL NUCLEAR MAGNETIC RESONANCE SPECTRAL FITTING
CATTATAC
>pdb|1D42|A Chain A, SOLUTION STRUCTURE OF [D(GTATATAC)]2 VIA RESTRAINED MOLECULAR DYNAMICS SIMULATIONS WITH NUCLEAR MAGNETIC RESONANCE CONSTRAINTS DERIVED FROM RELAXATION MATRIX ANALYSIS OF TWO-DIMENSIONAL NUCLEAR OVERHAUSER EFFECT EXPERIMENTS
GTATATAC
>pdb|1D19|B Chain B, SOLUTION CONFORMATION OF PURINE-PYRIMIDINE DNA OCTAMERS USING NUCLEAR MAGNETIC RESONANCE, RESTRAINED MOLECULAR DYNAMICS AND NOE-BASED REFINEMENT
GTACGTAC
>pdb|1D19|A Chain A, SOLUTION CONFORMATION OF PURINE-PYRIMIDINE DNA OCTAMERS USING NUCLEAR MAGNETIC RESONANCE, RESTRAINED MOLECULAR DYNAMICS AND NOE-BASED REFINEMENT
GTACGTAC
>pdb|1D18|B Chain B, SOLUTION CONFORMATION OF PURINE-PYRIMIDINE DNA OCTAMERS USING NUCLEAR MAGNETIC RESONANCE, RESTRAINED MOLECULAR DYNAMICS AND NOE-BASED REFINEMENT
CATGCATG
>pdb|1D18|A Chain A, SOLUTION CONFORMATION OF PURINE-PYRIMIDINE DNA OCTAMERS USING NUCLEAR MAGNETIC RESONANCE, RESTRAINED MOLECULAR DYNAMICS AND NOE-BASED REFINEMENT
CATGCATG
>pdb|7VBA|R Chain R, Structure of the pre state human RNA Polymerase I Elongation Complex
NGCTGACT
>pdb|7LCD|P Chain P, Crystal structure of human polymerase eta complexed with syn N7-acetophenoneguanine
AGTGTGAG
>pdb|7CGM|B Chain B, Crystal Structure of PUF-8 in Complex with PBE-RNA
NGTATATA
>pdb|7CGL|B Chain B, Crystal Structure of PUF-8 in Complex with PBE-RNA
NGTACATA
>pdb|7CGK|B Chain B, Crystal Structure of PUF-8 in Complex with PBE-RNA
NGTAAATA
>pdb|7CGJ|B Chain B, Crystal Structure of PUF-8 in Complex with PBE-RNA
NGTAGATA
>pdb|7CGI|B Chain B, Crystal Structure of PUF-8 in Complex with PBE-RNA
NGTATATA
>pdb|7CGH|B Chain B, Crystal Structure of PUF-8 in Complex with PBE-RNA
NGTACATA
>pdb|7CGG|B Chain B, Crystal Structure of PUF-8 in Complex with PBE-RNA
NGTAAATA
>pdb|7CGF|B Chain B, Crystal Structure of PUF-8 in Complex with PBE-RNA
NGTAGATA
>pdb|1G2J|A Chain A, RNA OCTAMER R(CCCP*GGGG) CONTAINING PHENYL RIBONUCLEOTIDE
CCCNGGGG
>pdb|209D|B Chain B, Structural, physical and biological characteristics of RNA:DNA binding agent N8-actinomycin D
GAAGCTTC
>pdb|209D|A Chain A, Structural, physical and biological characteristics of RNA:DNA binding agent N8-actinomycin D
GAAGCTTC
>pdb|7L69|P Chain P, Crystal structure of human polymerase eta complexed with syn N7-benzylguanine
AGTGTGAG
>pdb|7OSM|mRNA Chain mRNA, Intermediate translocation complex of 80 S.cerevisiae ribosome with eEF2 and ligands
NTGTTCAA
>pdb|7OHM|B Chain B, A self-complementary DNA dodecamer duplex contaning 5-hydroxymethylcitosine
CGANGTCG
>pdb|7OHM|A Chain A, A self-complementary DNA dodecamer duplex contaning 5-hydroxymethylcitosine
CGANGTCG
>pdb|7OHJ|B Chain B, A self-complementary DNA dodecamer duplex contaning 5-hydroxymethylcitosine
CGACGTCG
>pdb|7OHJ|A Chain A, A self-complementary DNA dodecamer duplex contaning 5-hydroxymethylcitosine
CGACGTCG
>PA339783.1 JP 2021521851-A/11: GENE THERAPY CONSTRUCTS AND METHODS OF USE
GCAAGATG
>PA277201.1 WO 2021182517-A/14: A single-stranded nucleic acids and a composition for inducing -1 frameshift
TAGTGTGG
>PA277200.1 WO 2021182517-A/13: A single-stranded nucleic acids and a composition for inducing -1 frameshift
CCGCATTA
>pdb|7M50|kk Chain kk, Crystallographic structure of a cubic crystal form of STMV grown from ammonium sulfate
NTTTTTTT
>pdb|7M50|TT Chain TT, Crystallographic structure of a cubic crystal form of STMV grown from ammonium sulfate
NAAAAAAA
>pdb|7M50|n Chain n, Crystallographic structure of a cubic crystal form of STMV grown from ammonium sulfate
NTTTTTTT
>pdb|7M50|m Chain m, Crystallographic structure of a cubic crystal form of STMV grown from ammonium sulfate
NTTTTTTT
>pdb|7M50|V Chain V, Crystallographic structure of a cubic crystal form of STMV grown from ammonium sulfate
NAAAAAAA
>pdb|7M50|P Chain P, Crystallographic structure of a cubic crystal form of STMV grown from ammonium sulfate
NAAAAAAA
>pdb|7M3T|qq Chain qq, Crystallographic structure of a cubic crystal of STMV (80.7 degree rotation about 111) grown from chloride
NTTTTTTT
>pdb|7M3T|n Chain n, Crystallographic structure of a cubic crystal of STMV (80.7 degree rotation about 111) grown from chloride
NTTTTTTT
>pdb|5BKN|n Chain n, Crystallographic structure of a cubic crystal form of STMV (84.5 degree rotation) grown from chloride
NTTTTTTT
>pdb|5BKN|a Chain a, Crystallographic structure of a cubic crystal form of STMV (84.5 degree rotation) grown from chloride
NAAAAAAA
>pdb|5BKN|S Chain S, Crystallographic structure of a cubic crystal form of STMV (84.5 degree rotation) grown from chloride
NAAAAAAA
>pdb|5BKN|P Chain P, Crystallographic structure of a cubic crystal form of STMV (84.5 degree rotation) grown from chloride
NAAAAAAA
>OF189129.1 KR 1020210005154-A/44: GENE THERAPY CONSTRUCTS AND METHODS OF USE
GCAAGATG
>OF188167.1 KR 1020210005661-A/186: PATHOGEN-RESISTANT ANIMALS HAVING MODIFIED AMINOPEPTIDASE N (ANPEP) GENES
NNGTNNNN
>OF188160.1 KR 1020210005661-A/179: PATHOGEN-RESISTANT ANIMALS HAVING MODIFIED AMINOPEPTIDASE N (ANPEP) GENES
GGGGCTTA
>OF188024.1 KR 1020210005661-A/39: PATHOGEN-RESISTANT ANIMALS HAVING MODIFIED AMINOPEPTIDASE N (ANPEP) GENES
CTGGGGGG
>OF187815.1 KR 1020210005090-A/5: CHIMERIC VECTORS
CAAAGGGT
>OF267165.1 KR 1020210043634-A/103: COMPOSITIONS AND METHODS FOR IMPROVING LIBRARY ENRICHMENT
TTTTTTTT
>OF265886.1 KR 1020210042128-A/121: NUCLEIC ACID MOLECULES AND USES THEREOF FOR NON-VIRAL GENE THERAPY
ATCAGCCT
>OF265853.1 KR 1020210042128-A/31: NUCLEIC ACID MOLECULES AND USES THEREOF FOR NON-VIRAL GENE THERAPY
ATTTTTAA
>OF265852.1 KR 1020210042128-A/30: NUCLEIC ACID MOLECULES AND USES THEREOF FOR NON-VIRAL GENE THERAPY
ATTTTATT
>OF140235.1 KR 1020210028134-A/96: Composition for diagnosis or treatment of a condition associated with increased activity of eIF4E comprising an eIF4E inhibitor
ACAWYAGC
>OF260498.1 KR 1020210057019-A/4: CIRCULARIZED ENGINEERED RNA AND METHODS
TCACATGG
>OF259547.1 KR 1020210039401-A/20: COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF
CGGCTATT
>OF259546.1 KR 1020210039401-A/19: COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF
AATAGCCG
>OF295773.1 KR 1020210070389-A/570: Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
GGCGCGCC
>OF254146.1 KR 1020210030965-A/15: GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE
AGNNATGN
>OF290850.1 KR 1020210077732-A/503: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GTGGCCAC
>OF290847.1 KR 1020210077732-A/500: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
ACTCCCTC
>OF290846.1 KR 1020210077732-A/499: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
AATCCCTT
>OF290841.1 KR 1020210077732-A/494: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
ACAAGGGT
>OF290840.1 KR 1020210077732-A/493: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
AGGCCCAG
>OF290835.1 KR 1020210077732-A/488: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGGCCCGC
>OF290832.1 KR 1020210077732-A/485: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GTACCCTC
>OF290831.1 KR 1020210077732-A/484: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGGGCCAG
>OF290655.1 KR 1020210077732-A/304: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
ATGATGCG
>OF290516.1 KR 1020210077732-A/165: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
AGATCCAC
>OF290512.1 KR 1020210077732-A/161: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
AAGCCCAA
>OF290508.1 KR 1020210077732-A/157: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
AGGCCCAG
>OF290504.1 KR 1020210077732-A/153: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGGTCCAT
>OF290500.1 KR 1020210077732-A/149: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGGCCCGC
>OF290496.1 KR 1020210077732-A/145: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CGGGCCAG
>OF290492.1 KR 1020210077732-A/141: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGGGCCAG
>OF290488.1 KR 1020210077732-A/137: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGGGCCTC
>OF290484.1 KR 1020210077732-A/133: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CAAGCCAA
>OF290480.1 KR 1020210077732-A/129: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
AATTCCGA
>OF290476.1 KR 1020210077732-A/125: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGGTCACT
>OF290472.1 KR 1020210077732-A/121: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GTCACTCC
>OF290468.1 KR 1020210077732-A/117: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CTGTCCGG
>OF290464.1 KR 1020210077732-A/113: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CTCCCCGC
>OF290460.1 KR 1020210077732-A/109: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
TCCCCGCT
>OF290456.1 KR 1020210077732-A/105: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
TCTTCGAG
>OF290452.1 KR 1020210077732-A/101: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CCAGCCAA
>OF290448.1 KR 1020210077732-A/97: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGCGCGAC
>OF290444.1 KR 1020210077732-A/93: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CCCGCAAA
>OF290440.1 KR 1020210077732-A/89: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
TGGGCGTC
>OF290436.1 KR 1020210077732-A/85: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
AGGGCTGC
>OF290432.1 KR 1020210077732-A/81: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGGGCCCC
>OF290428.1 KR 1020210077732-A/77: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGGTCACT
>OF290424.1 KR 1020210077732-A/73: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGCACCAT
>OF290420.1 KR 1020210077732-A/69: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
TTTTCCTG
>OF290416.1 KR 1020210077732-A/65: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
ACGTCCTC
>OF290412.1 KR 1020210077732-A/61: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CAAGCCTT
>OF290408.1 KR 1020210077732-A/57: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CTTTCCCT
>OF290404.1 KR 1020210077732-A/53: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CTATCCAA
>OF290400.1 KR 1020210077732-A/49: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
TTTCCCTC
>OF290396.1 KR 1020210077732-A/45: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CACGCCCG
>OF290392.1 KR 1020210077732-A/41: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
ATTTCCTC
>OF290388.1 KR 1020210077732-A/37: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GACACCCC
>OF290384.1 KR 1020210077732-A/33: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
TGACCCGA
>OF290380.1 KR 1020210077732-A/29: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGGGCCAC
>OF290376.1 KR 1020210077732-A/25: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GGGCCCTA
>OF290372.1 KR 1020210077732-A/21: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CAGCCCAA
>OF290368.1 KR 1020210077732-A/17: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
GAGGCCTA
>OF290364.1 KR 1020210077732-A/13: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
TAGACGAA
>OF290360.1 KR 1020210077732-A/9: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CCTCCACC
>OF209794.1 KR 1020210040911-A/96: Composition for diagnosis or treatment of a condition associated with increased activity of eIF4E comprising an eIF4E inhibitor
ACAWYAGC
>OF288016.1 KR 1020210049986-A/8: CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES
TTTGAATT
>OF287840.1 KR 1020210069075-A/20: METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY
NNNNGCTT
>OF287839.1 KR 1020210069075-A/19: METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY
NNNNGATT
>OF287828.1 KR 1020210069075-A/7: METHODS AND COMPOSITIONS FOR OCULAR CELL THERAPY
NNNNGATT
>OF209559.1 KR 1020210040910-A/96: Composition for diagnosis or treatment of a condition associated with increased activity of eIF4E comprising an eIF4E inhibitor
ACAWYAGC
>OF209324.1 KR 1020210040909-A/96: Composition for diagnosis or treatment of a condition associated with increased activity of eIF4E comprising an eIF4E inhibitor
ACAWYAGC
>OF167797.1 KR 1020210005074-A/39: METHODS FOR PROTECTING PORCINE FETUSES FROM INFECTION WITH VIRUS
CTGGGGGG
>OF247449.1 KR 1020210016078-A/2307: CHIRAL CONTROL
AACGTTCT
>OF247448.1 KR 1020210016078-A/2306: CHIRAL CONTROL
TCATCGAT
>OF247445.1 KR 1020210016078-A/2303: CHIRAL CONTROL
CAGGTAAG
>OF245179.1 KR 1020210016078-A/34: CHIRAL CONTROL
TCAACGTC
>OF245177.1 KR 1020210016078-A/32: CHIRAL CONTROL
CCAACGTT
>OF245175.1 KR 1020210016078-A/30: CHIRAL CONTROL
TCTTCGAA
>OF245174.1 KR 1020210016078-A/29: CHIRAL CONTROL
TCTTCGAT
>OF245173.1 KR 1020210016078-A/28: CHIRAL CONTROL
TCAGCGCT
>OF245172.1 KR 1020210016078-A/27: CHIRAL CONTROL
TCAAGCTT
>OF245171.1 KR 1020210016078-A/26: CHIRAL CONTROL
TCAACGTT
>OF241070.1 KR 1020210013303-A/2943: USING TRUNCATED GUIDE RNAS (TRU-GRNAS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING
ACAAGATG
>OF240889.1 KR 1020210013303-A/2762: USING TRUNCATED GUIDE RNAS (TRU-GRNAS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING
TAGCTGTT
>OF201295.1 KR 1020210013133-A/20: HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES
GTTGGTGT
>OF201294.1 KR 1020210013133-A/19: HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES
ACACCAAC
>OF201289.1 KR 1020210013133-A/14: HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES
ACACCAAC
>OF201288.1 KR 1020210013133-A/13: HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES
GTTGGTGT
>OF201287.1 KR 1020210013133-A/12: HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES
AGACGCAC
>OF201286.1 KR 1020210013133-A/11: HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES
GTGCGTCT
>OF201279.1 KR 1020210013133-A/4: HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES
CGTCAGGC
>OF201278.1 KR 1020210013133-A/3: HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES
GCCTGACG
>OF201277.1 KR 1020210013133-A/2: HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES
CAGGAGCA
>OF201276.1 KR 1020210013133-A/1: HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES
TGCTCCTG
>pdb|7A9T|L Chain L, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|7A9T|K Chain K, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|7A9S|L Chain L, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|7A9S|K Chain K, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|7A9R|N Chain N, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|7A9R|M Chain M, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|7A9Q|L Chain L, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|7A9Q|K Chain K, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|7A9P|N Chain N, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|7A9P|M Chain M, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|7A9O|L Chain L, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|7A9O|K Chain K, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|7A9N|L Chain L, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|7A9N|K Chain K, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|7A9L|N Chain N, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|7A9L|M Chain M, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|6ZX8|L Chain L, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|6ZX8|K Chain K, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|6ZX5|L Chain L, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|6ZX5|K Chain K, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|6ZWU|N Chain N, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|6ZWU|M Chain M, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|6ZW3|N Chain N, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|6ZW3|M Chain M, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|6ZRS|L Chain L, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|6ZRS|K Chain K, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|6ZRL|N Chain N, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|6ZRL|M Chain M, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|6ZR1|L Chain L, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|6ZR1|K Chain K, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|6ZQ9|L Chain L, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|6ZQ9|K Chain K, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|6ZPF|L Chain L, Racemic compound of RNA duplexes.
CCGCCTGG
>pdb|6ZPF|K Chain K, Racemic compound of RNA duplexes.
CTGGGCGG
>pdb|7DFH|P Chain P, Structure of COVID-19 RNA-dependent RNA polymerase bound to ribavirin
NCTATGTG
>pdb|1XYI|C Chain C, Hyperthermophile chromosomal protein Sac7d double mutant Val26Ala/Met29Ala in complex with DNA GCGATCGC
GCGATCGC
>pdb|1XYI|B Chain B, Hyperthermophile chromosomal protein Sac7d double mutant Val26Ala/Met29Ala in complex with DNA GCGATCGC
GCGATCGC
>pdb|1WTX|C Chain C, Hyperthermophile chromosomal protein SAC7D single mutant V26A in complex with DNA GTAATTAC
GTAATTAC
>pdb|1WTX|B Chain B, Hyperthermophile chromosomal protein SAC7D single mutant V26A in complex with DNA GTAATTAC
GTAATTAC
>pdb|1WTW|C Chain C, Hyperthermophile chromosomal protein SAC7D single mutant V26A in complex with DNA GCGATCGC
GCGATCGC
>pdb|1WTW|B Chain B, Hyperthermophile chromosomal protein SAC7D single mutant V26A in complex with DNA GCGATCGC
GCGATCGC
>pdb|1WTV|C Chain C, Hyperthermophile chromosomal protein SAC7D single mutant M29A in complex with DNA GTAATTAC
GTAATTAC
>pdb|1WTV|B Chain B, Hyperthermophile chromosomal protein SAC7D single mutant M29A in complex with DNA GTAATTAC
GTAATTAC
>pdb|1WTR|C Chain C, Hyperthermophile chromosomal protein SAC7D single mutant M29A in complex with DNA GCGATCGC
GCGATCGC
>pdb|1WTR|B Chain B, Hyperthermophile chromosomal protein SAC7D single mutant M29A in complex with DNA GCGATCGC
GCGATCGC
>pdb|1WTQ|C Chain C, Hyperthermophile chromosomal protein SAC7D single mutant M29F in complex with DNA GTAATTAC
GTAATTAC
>pdb|1WTQ|B Chain B, Hyperthermophile chromosomal protein SAC7D single mutant M29F in complex with DNA GTAATTAC
GTAATTAC
>pdb|1WTP|F Chain F, Hyperthermophile chromosomal protein SAC7D single mutant M29F in complex with DNA GCGA(UBr)CGC
GCGANCGC
>pdb|1WTP|E Chain E, Hyperthermophile chromosomal protein SAC7D single mutant M29F in complex with DNA GCGA(UBr)CGC
GCGANCGC
>pdb|1WTP|D Chain D, Hyperthermophile chromosomal protein SAC7D single mutant M29F in complex with DNA GCGA(UBr)CGC
GCGANCGC
>pdb|1WTP|C Chain C, Hyperthermophile chromosomal protein SAC7D single mutant M29F in complex with DNA GCGA(UBr)CGC
GCGANCGC
>pdb|1WTO|C Chain C, Hyperthermophile chromosomal protein SAC7D double mutant V26F/M29F in complex with DNA GCGATCGC
GCGATCGC
>pdb|1WTO|B Chain B, Hyperthermophile chromosomal protein SAC7D double mutant V26F/M29F in complex with DNA GCGATCGC
GCGATCGC
>pdb|1OUP|F Chain F, Crystal structure of the periplasmic endonuclease Vvn complexed with octamer double stranded DNA
GCGATCGC
>pdb|1OUP|D Chain D, Crystal structure of the periplasmic endonuclease Vvn complexed with octamer double stranded DNA
GCGATCGC
>pdb|1OUP|C Chain C, Crystal structure of the periplasmic endonuclease Vvn complexed with octamer double stranded DNA
GCGATCGC
>pdb|2N96|Y Chain Y, An unexpected mode of small molecule DNA binding provides the structural basis for DNA cleavage by the potent antiproliferative agent (-)-lomaiviticin A
GCTATAGC
>pdb|2N96|X Chain X, An unexpected mode of small molecule DNA binding provides the structural basis for DNA cleavage by the potent antiproliferative agent (-)-lomaiviticin A
GCTATAGC
>pdb|2KZM|B Chain B, KLENOW FRAGMENT WITH NORMAL SUBSTRATE AND ZINC AND MANGANESE
GCTTACGC
>pdb|1EVW|P Chain P, L116A MUTANT OF THE HOMING ENDONUCLEASE I-PPOI COMPLEXED TO HOMING SITE DNA.
NGTAGCCA
>pdb|1EVW|N Chain N, L116A MUTANT OF THE HOMING ENDONUCLEASE I-PPOI COMPLEXED TO HOMING SITE DNA.
NAGAGTCA
>pdb|1EVW|O Chain O, L116A MUTANT OF THE HOMING ENDONUCLEASE I-PPOI COMPLEXED TO HOMING SITE DNA.
NGTAGCCA
>pdb|1EVW|M Chain M, L116A MUTANT OF THE HOMING ENDONUCLEASE I-PPOI COMPLEXED TO HOMING SITE DNA.
NAGAGTCA
>pdb|1QSL|B Chain B, KLENOW FRAGMENT COMPLEXED WITH SINGLE-STRANDED SUBSTRATE AND EUROPIUM (III) ION
GCTTACGC
>MQ265094.1 Sequence 4 from Patent WO2021209743
TGACTCAG
>MQ265091.1 Sequence 1 from Patent WO2021209743
TGACGTCA
>MQ262299.1 Sequence 159 from Patent WO2021209813
MTACYYCT
>MQ262298.1 Sequence 158 from Patent WO2021209813
TACCCCTA
>MQ262284.1 Sequence 144 from Patent WO2021209813
WAKRRKTA
>pdb|1YFV|B Chain B, STRUCTURE OF (5'-R(GP*GP*CP*GP*AP*GP*CP*C)-3')2 BY 2-D NMR, 1 STRUCTURE
GGCGAGCC
>pdb|1YFV|A Chain A, STRUCTURE OF (5'-R(GP*GP*CP*GP*AP*GP*CP*C)-3')2 BY 2-D NMR, 1 STRUCTURE
GGCGAGCC
>pdb|1M3H|C Chain C, Crystal Structure of Hogg1 D268E Mutant with Product Oligonucleotide
NCGTCCAN
>pdb|1I7D|B Chain B, NONCOVALENT COMPLEX OF E.COLI DNA TOPOISOMERASE III WITH AN 8-BASE SINGLE-STRANDED DNA OLIGONUCLEOTIDE
CGCAACTT
>PA268690.1 WO 2021132528-A/68: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGACGTC
>PA268686.1 WO 2021132528-A/64: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGCCGTC
>PA268685.1 WO 2021132528-A/63: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
CCGACGTT
>PA268684.1 WO 2021132528-A/62: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGCCGTT
>PA268683.1 WO 2021132528-A/61: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGGCGTT
>PA268682.1 WO 2021132528-A/60: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGTCGTT
>PA268646.1 WO 2021132528-A/24: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCTACGTT
>PA268643.1 WO 2021132528-A/21: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGACGTT
>PA268631.1 WO 2021132528-A/9: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGAGCGT
>PA268625.1 WO 2021132528-A/3: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
GATCGTCG
>MQ216390.1 Sequence 70 from Patent WO2021195214
GCCTCAGT
>MQ216389.1 Sequence 69 from Patent WO2021195214
ACTGAGGC
>MQ224149.1 Sequence 70 from Patent WO2021195218
GCCTCAGT
>MQ224148.1 Sequence 69 from Patent WO2021195218
ACTGAGGC
>MQ220457.1 Sequence 4 from Patent WO2021191628
TGACTCAG
>MQ220454.1 Sequence 1 from Patent WO2021191628
TGACGTCA
>pdb|3E3J|Z Chain Z, Crystal Structure of an Intermediate Complex of T7 RNAP and 8nt of RNA
GGGAGTAA
>pdb|3E3J|R Chain R, Crystal Structure of an Intermediate Complex of T7 RNAP and 8nt of RNA
GGGAGTAA
>pdb|3BX3|D Chain D, Puf4 T650C/C724R Mutant bound to Cox17 RNA 3' UTR recognition sequence
TGTATATA
>pdb|3BX3|C Chain C, Puf4 T650C/C724R Mutant bound to Cox17 RNA 3' UTR recognition sequence
TGTATATA
>pdb|3BSO|P Chain P, Norwalk Virus polymerase bound to cytidine 5'-triphosphate and primer-template RNA
TGCCCGGG
>pdb|3BSN|P Chain P, Norwalk Virus polymerase bound to 5-nitrocytidine triphosphate and primer-template RNA
TGCCCGGG
>pdb|6KI3|G Chain G, The crystal structure of AsfvAP:dF commplex
NCGACGAG
>pdb|6KI3|D Chain D, The crystal structure of AsfvAP:dF commplex
NCGACGAG
>pdb|3KNC|B Chain B, Crystal structure of the CeNA-RNA hybrid octamer ce(GCGTAGCG):r(CGCUACGC)
CGCTACGC
>pdb|3LOB|R Chain R, Crystal Structure of Flock House Virus calcium mutant
TTTATCTN
>pdb|3KHC|C Chain C, Crystal Structure of Escherichia coli AlkB in complex with ssDNA containing a 1-methylguanine lesion
NANTGCCT
>pdb|3H5Y|P Chain P, Norovirus polymerase+primer/template+CTP complex at 6 mM MnCl2
TGCCCGGG
>pdb|3H5X|P Chain P, Crystal Structure of 2'-amino-2'-deoxy-cytidine-5'-triphosphate bound to Norovirus GII RNA polymerase
TGCCCGGG
>MQ209543.1 Sequence 213 from Patent EP3814505
AACCACAA
>MQ209538.1 Sequence 208 from Patent EP3814505
GCAGAACA
>MQ209536.1 Sequence 206 from Patent EP3814505
GACAACAG
>MQ205073.1 Sequence 16 from Patent WO2021181108
TGGTRAGT
>MQ199298.1 Sequence 542 from Patent EP3877528
TTAATTAA
>MQ199291.1 Sequence 535 from Patent EP3877528
GCCTCAGT
>MQ199288.1 Sequence 532 from Patent EP3877528
ACTGAGGC
>MQ198815.1 Sequence 7 from Patent EP3877528
GTTTAAAC
>MQ193569.1 Sequence 16 from Patent EP3868874
GGCCGGCC
>MQ193568.1 Sequence 15 from Patent EP3868874
CCTGCAGG
>PA267642.1 JP 2021509818-A/2: USE OF ANP32 PROTEIN IN MAINTAINING INFLUENZA VIRUS POLYMERASE ACTIVITY IN HOST
GCGGCCGC
>PA266570.1 WO 2021125311-A/378: ANTISENSE NUCLEIC ACID CAUSING EXON SKIPPING
GGTAGGGC
>PA264428.1 WO 2021085554-A/6: METHOD FOR PRODUCING NUCLEIC ACID MOLECULE, BIOMATERIAL, AND METHOD FOR PRODUCING BIOMATERIAL
AGTTTWAD
>PA264339.1 WO 2021084782-A/6: METHOD FOR PRODUCING NUCLEIC ACID MOLECULE, BIOMATERIAL, AND METHOD FOR PRODUCING BIOMATERIAL
AGTTTWAD
>MQ165614.1 Sequence 16 from Patent WO2021156370
TTTTTTTT
>MQ165600.1 Sequence 2 from Patent WO2021156370
TTTTTTTT
>MQ164343.1 Sequence 60 from Patent WO2021156316
TCACACCT
>MQ164317.1 Sequence 34 from Patent WO2021156316
TTACGTAA
>MQ163813.1 Sequence 503 from Patent EP3867367
GTGGCCAC
>MQ163810.1 Sequence 500 from Patent EP3867367
ACTCCCTC
>MQ163809.1 Sequence 499 from Patent EP3867367
AATCCCTT
>MQ163804.1 Sequence 494 from Patent EP3867367
ACAAGGGT
>MQ163803.1 Sequence 493 from Patent EP3867367
AGGCCCAG
>MQ163798.1 Sequence 488 from Patent EP3867367
GGGCCCGC
>MQ163795.1 Sequence 485 from Patent EP3867367
GTACCCTC
>MQ163794.1 Sequence 484 from Patent EP3867367
GGGGCCAG
>MQ164293.1 Sequence 10 from Patent WO2021156316
TGACGTCA
>MQ163415.1 Sequence 101 from Patent EP3867367
CCAGCCAA
>MQ163411.1 Sequence 97 from Patent EP3867367
GGCGCGAC
>MQ163407.1 Sequence 93 from Patent EP3867367
CCCGCAAA
>MQ163403.1 Sequence 89 from Patent EP3867367
TGGGCGTC
>MQ163399.1 Sequence 85 from Patent EP3867367
AGGGCTGC
>MQ163395.1 Sequence 81 from Patent EP3867367
GGGGCCCC
>MQ163391.1 Sequence 77 from Patent EP3867367
GGGTCACT
>MQ163387.1 Sequence 73 from Patent EP3867367
GGCACCAT
>MQ163383.1 Sequence 69 from Patent EP3867367
TTTTCCTG
>MQ163379.1 Sequence 65 from Patent EP3867367
ACGTCCTC
>MQ163375.1 Sequence 61 from Patent EP3867367
CAAGCCTT
>MQ163371.1 Sequence 57 from Patent EP3867367
CTTTCCCT
>MQ163367.1 Sequence 53 from Patent EP3867367
CTATCCAA
>MQ163363.1 Sequence 49 from Patent EP3867367
TTTCCCTC
>MQ163359.1 Sequence 45 from Patent EP3867367
CACGCCCG
>MQ163355.1 Sequence 41 from Patent EP3867367
ATTTCCTC
>MQ163351.1 Sequence 37 from Patent EP3867367
GACACCCC
>MQ163347.1 Sequence 33 from Patent EP3867367
TGACCCGA
>MQ163343.1 Sequence 29 from Patent EP3867367
GGGGCCAC
>MQ163339.1 Sequence 25 from Patent EP3867367
GGGCCCTA
>MQ163335.1 Sequence 21 from Patent EP3867367
CAGCCCAA
>MQ163331.1 Sequence 17 from Patent EP3867367
GAGGCCTA
>MQ163327.1 Sequence 13 from Patent EP3867367
TAGACGAA
>MQ163323.1 Sequence 9 from Patent EP3867367
CCTCCACC
>MQ163618.1 Sequence 304 from Patent EP3867367
ATGATGCG
>MQ163479.1 Sequence 165 from Patent EP3867367
AGATCCAC
>MQ163475.1 Sequence 161 from Patent EP3867367
AAGCCCAA
>MQ163471.1 Sequence 157 from Patent EP3867367
AGGCCCAG
>MQ163467.1 Sequence 153 from Patent EP3867367
GGGTCCAT
>MQ163463.1 Sequence 149 from Patent EP3867367
GGGCCCGC
>MQ163459.1 Sequence 145 from Patent EP3867367
CGGGCCAG
>MQ163455.1 Sequence 141 from Patent EP3867367
GGGGCCAG
>MQ163451.1 Sequence 137 from Patent EP3867367
GGGGCCTC
>MQ163447.1 Sequence 133 from Patent EP3867367
CAAGCCAA
>MQ163443.1 Sequence 129 from Patent EP3867367
AATTCCGA
>MQ163439.1 Sequence 125 from Patent EP3867367
GGGTCACT
>MQ163435.1 Sequence 121 from Patent EP3867367
GTCACTCC
>MQ163431.1 Sequence 117 from Patent EP3867367
CTGTCCGG
>MQ163427.1 Sequence 113 from Patent EP3867367
CTCCCCGC
>MQ163423.1 Sequence 109 from Patent EP3867367
TCCCCGCT
>MQ163419.1 Sequence 105 from Patent EP3867367
TCTTCGAG
>MQ144985.1 Sequence 27 from Patent WO2021152587
GCCACGTG
>MQ144978.1 Sequence 20 from Patent WO2021152587
CAGCGRNV
>MQ144499.1 Sequence 25 from Patent WO2021155171
CGGCTATT
>MQ144498.1 Sequence 24 from Patent WO2021155171
AATAGCCG
>MQ135165.1 Sequence 7 from Patent WO2021148809
TTTTTTTT
>OF066201.1 KR 1020200091499-A/36: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
GTTTTTGT
>OF066183.1 KR 1020200091499-A/18: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
TATTTGAG
>OF066182.1 KR 1020200091499-A/17: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
GATTTGAG
>OF066181.1 KR 1020200091499-A/16: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
CATTTGAG
>OF066180.1 KR 1020200091499-A/15: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
AATTTGAG
>OF066170.1 KR 1020200091499-A/5: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
ATTTGAGG
>OF066168.1 KR 1020200091499-A/3: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
TATGAAAA
>OF102587.1 KR 1020200124250-A/124: CONTROLLED EXPRESSION OF TRANSGENES USING CLOSE-ENDED DNA (CEDNA) VECTORS
TTAATTAA
>OF102586.1 KR 1020200124250-A/123: CONTROLLED EXPRESSION OF TRANSGENES USING CLOSE-ENDED DNA (CEDNA) VECTORS
GTTTAAAC
>OF102552.1 KR 1020200124250-A/70: CONTROLLED EXPRESSION OF TRANSGENES USING CLOSE-ENDED DNA (CEDNA) VECTORS
GCCTCAGT
>OF102551.1 KR 1020200124250-A/69: CONTROLLED EXPRESSION OF TRANSGENES USING CLOSE-ENDED DNA (CEDNA) VECTORS
ACTGAGGC
>OF019906.1 KR 1020200117827-A/324: A cancer diagnosis marker based on ATAC-Seq and Method using the same
CCACTCCT
>OF019905.1 KR 1020200117827-A/323: A cancer diagnosis marker based on ATAC-Seq and Method using the same
TTGACCCT
>OF019904.1 KR 1020200117827-A/322: A cancer diagnosis marker based on ATAC-Seq and Method using the same
TGGTCACA
>OF019903.1 KR 1020200117827-A/321: A cancer diagnosis marker based on ATAC-Seq and Method using the same
TGGGTTTC
>OF019902.1 KR 1020200117827-A/320: A cancer diagnosis marker based on ATAC-Seq and Method using the same
GTGTGGTG
>OF019901.1 KR 1020200117827-A/319: A cancer diagnosis marker based on ATAC-Seq and Method using the same
AGGTTGGG
>OF019900.1 KR 1020200117827-A/318: A cancer diagnosis marker based on ATAC-Seq and Method using the same
GAGGGGTT
>OF019899.1 KR 1020200117827-A/317: A cancer diagnosis marker based on ATAC-Seq and Method using the same
TGCTGGGT
>OF019898.1 KR 1020200117827-A/316: A cancer diagnosis marker based on ATAC-Seq and Method using the same
CCGTTTGT
>OF019897.1 KR 1020200117827-A/315: A cancer diagnosis marker based on ATAC-Seq and Method using the same
TGGATCTG
>OF019896.1 KR 1020200117827-A/314: A cancer diagnosis marker based on ATAC-Seq and Method using the same
ACCACTGT
>OF019895.1 KR 1020200117827-A/313: A cancer diagnosis marker based on ATAC-Seq and Method using the same
GTCGTGAT
>OF019894.1 KR 1020200117827-A/312: A cancer diagnosis marker based on ATAC-Seq and Method using the same
GTAGAGGA
>OF019893.1 KR 1020200117827-A/311: A cancer diagnosis marker based on ATAC-Seq and Method using the same
AAGAGGCA
>OF019892.1 KR 1020200117827-A/310: A cancer diagnosis marker based on ATAC-Seq and Method using the same
CGAGGCTG
>OF019891.1 KR 1020200117827-A/309: A cancer diagnosis marker based on ATAC-Seq and Method using the same
GCTACGCT
>OF019890.1 KR 1020200117827-A/308: A cancer diagnosis marker based on ATAC-Seq and Method using the same
CAGAGAGG
>OF019889.1 KR 1020200117827-A/307: A cancer diagnosis marker based on ATAC-Seq and Method using the same
CTCTCTAC
>OF019888.1 KR 1020200117827-A/306: A cancer diagnosis marker based on ATAC-Seq and Method using the same
TAGGCATG
>OF019887.1 KR 1020200117827-A/305: A cancer diagnosis marker based on ATAC-Seq and Method using the same
GGACTCCT
>OF019886.1 KR 1020200117827-A/304: A cancer diagnosis marker based on ATAC-Seq and Method using the same
TCCTGAGC
>OF019885.1 KR 1020200117827-A/303: A cancer diagnosis marker based on ATAC-Seq and Method using the same
AGGCAGAA
>OF019884.1 KR 1020200117827-A/302: A cancer diagnosis marker based on ATAC-Seq and Method using the same
CGTACTAG
>OF019883.1 KR 1020200117827-A/301: A cancer diagnosis marker based on ATAC-Seq and Method using the same
TAAGGCGA
>OF019578.1 KR 1020200081225-A/8: Chimeric strain of porcine reproductive and respiratory syndrome virus and antiviral vaccines including the same
TTAATTAA
>OF019577.1 KR 1020200081225-A/7: Chimeric strain of porcine reproductive and respiratory syndrome virus and antiviral vaccines including the same
GGCGCGCC
>OF017458.1 KR 1020200137636-A/863: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCTAGAGT
>OF017457.1 KR 1020200137636-A/862: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CTGCAGTT
>OF017456.1 KR 1020200137636-A/861: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGCCCTAT
>OF017455.1 KR 1020200137636-A/860: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GGGGGATT
>OF017454.1 KR 1020200137636-A/859: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCACAGTT
>OF017453.1 KR 1020200137636-A/858: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
ATACAAGT
>OF017452.1 KR 1020200137636-A/857: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CGGGTTAT
>OF017451.1 KR 1020200137636-A/856: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CGGATCCT
>OF017450.1 KR 1020200137636-A/855: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AATCTCAT
>OF017449.1 KR 1020200137636-A/854: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGCTGT
>OF017448.1 KR 1020200137636-A/853: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
ACCCGTAT
>OF017447.1 KR 1020200137636-A/852: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CTACAGTT
>OF017446.1 KR 1020200137636-A/851: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCCAGAGT
>OF017445.1 KR 1020200137636-A/850: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
ATGCCTTT
>OF017444.1 KR 1020200137636-A/849: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CTTAAACT
>OF017443.1 KR 1020200137636-A/848: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCTTGAGT
>OF017442.1 KR 1020200137636-A/847: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTTTGCT
>OF017441.1 KR 1020200137636-A/846: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAGAGGAT
>OF017440.1 KR 1020200137636-A/845: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GGAGTGTT
>OF017439.1 KR 1020200137636-A/844: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AACACCAT
>OF017438.1 KR 1020200137636-A/843: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GAATTGTT
>OF017437.1 KR 1020200137636-A/842: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCACATTT
>OF017436.1 KR 1020200137636-A/841: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GATTGTAT
>OF017435.1 KR 1020200137636-A/840: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GAGAACTT
>OF017434.1 KR 1020200137636-A/839: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTGCGTT
>OF017433.1 KR 1020200137636-A/838: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCCCTTTT
>OF017432.1 KR 1020200137636-A/837: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAGGCACT
>OF016595.1 KR 1020200137635-A/863: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCTAGAGT
>OF016594.1 KR 1020200137635-A/862: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CTGCAGTT
>OF016593.1 KR 1020200137635-A/861: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGCCCTAT
>OF016592.1 KR 1020200137635-A/860: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GGGGGATT
>OF016591.1 KR 1020200137635-A/859: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCACAGTT
>OF016590.1 KR 1020200137635-A/858: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
ATACAAGT
>OF016589.1 KR 1020200137635-A/857: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CGGGTTAT
>OF016588.1 KR 1020200137635-A/856: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CGGATCCT
>OF016587.1 KR 1020200137635-A/855: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AATCTCAT
>OF016586.1 KR 1020200137635-A/854: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGCTGT
>OF016585.1 KR 1020200137635-A/853: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
ACCCGTAT
>OF016584.1 KR 1020200137635-A/852: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CTACAGTT
>OF016583.1 KR 1020200137635-A/851: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCCAGAGT
>OF016582.1 KR 1020200137635-A/850: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
ATGCCTTT
>OF016581.1 KR 1020200137635-A/849: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CTTAAACT
>OF016580.1 KR 1020200137635-A/848: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCTTGAGT
>OF016579.1 KR 1020200137635-A/847: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTTTGCT
>OF016578.1 KR 1020200137635-A/846: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAGAGGAT
>OF016577.1 KR 1020200137635-A/845: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GGAGTGTT
>OF016576.1 KR 1020200137635-A/844: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AACACCAT
>OF016575.1 KR 1020200137635-A/843: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GAATTGTT
>OF016574.1 KR 1020200137635-A/842: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCACATTT
>OF016573.1 KR 1020200137635-A/841: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GATTGTAT
>OF016572.1 KR 1020200137635-A/840: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GAGAACTT
>OF016571.1 KR 1020200137635-A/839: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTGCGTT
>OF016570.1 KR 1020200137635-A/838: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCCCTTTT
>OF016569.1 KR 1020200137635-A/837: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAGGCACT
>OF097808.1 KR 1020200108501-A/167: PLANT REGULATORY ELEMENTS AND USES THEREOF
ACACGCTG
>OF097637.1 KR 1020200108500-A/167: PLANT REGULATORY ELEMENTS AND USES THEREOF
ACACGCTG
>OF015732.1 KR 1020200137634-A/863: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCTAGAGT
>OF015731.1 KR 1020200137634-A/862: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CTGCAGTT
>OF015730.1 KR 1020200137634-A/861: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGCCCTAT
>OF015729.1 KR 1020200137634-A/860: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GGGGGATT
>OF015728.1 KR 1020200137634-A/859: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCACAGTT
>OF015727.1 KR 1020200137634-A/858: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
ATACAAGT
>OF015726.1 KR 1020200137634-A/857: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CGGGTTAT
>OF015725.1 KR 1020200137634-A/856: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CGGATCCT
>OF015724.1 KR 1020200137634-A/855: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AATCTCAT
>OF015723.1 KR 1020200137634-A/854: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGCTGT
>OF015722.1 KR 1020200137634-A/853: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
ACCCGTAT
>OF015721.1 KR 1020200137634-A/852: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CTACAGTT
>OF015720.1 KR 1020200137634-A/851: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCCAGAGT
>OF015719.1 KR 1020200137634-A/850: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
ATGCCTTT
>OF015718.1 KR 1020200137634-A/849: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
CTTAAACT
>OF015717.1 KR 1020200137634-A/848: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCTTGAGT
>OF015716.1 KR 1020200137634-A/847: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTTTGCT
>OF015715.1 KR 1020200137634-A/846: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAGAGGAT
>OF015714.1 KR 1020200137634-A/845: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GGAGTGTT
>OF015713.1 KR 1020200137634-A/844: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AACACCAT
>OF015712.1 KR 1020200137634-A/843: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GAATTGTT
>OF015711.1 KR 1020200137634-A/842: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCACATTT
>OF015710.1 KR 1020200137634-A/841: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GATTGTAT
>OF015709.1 KR 1020200137634-A/840: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
GAGAACTT
>OF015708.1 KR 1020200137634-A/839: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTGCGTT
>OF015707.1 KR 1020200137634-A/838: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TCCCTTTT
>OF015706.1 KR 1020200137634-A/837: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAGGCACT
>OF096257.1 KR 1020200118089-A/31: USE OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII
ATTTTTAA
>OF096256.1 KR 1020200118089-A/30: USE OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII
ATTTTATT
>OF014349.1 KR 1020200127495-A/4: AMPLIFICATION STRUCTURE TARGETING RNA AND METHOD FOR AMPLIFYING NUCLEIC ACID USING SAME
CAGAGCCA
>OF013981.1 KR 1020200120329-A/7: COMPOSITION FOR DELIVERING OF ANTIGEN
GAATCCGC
>OF095700.1 KR 1020200120649-A/124: NON-VIRAL DNA VECTORS AND USES THEREOF FOR ANTIBODY AND FUSION PROTEIN PRODUCTION
TTAATTAA
>OF095699.1 KR 1020200120649-A/123: NON-VIRAL DNA VECTORS AND USES THEREOF FOR ANTIBODY AND FUSION PROTEIN PRODUCTION
GTTTAAAC
>OF095665.1 KR 1020200120649-A/70: NON-VIRAL DNA VECTORS AND USES THEREOF FOR ANTIBODY AND FUSION PROTEIN PRODUCTION
GCCTCAGT
>OF095664.1 KR 1020200120649-A/69: NON-VIRAL DNA VECTORS AND USES THEREOF FOR ANTIBODY AND FUSION PROTEIN PRODUCTION
ACTGAGGC
>OF011328.1 KR 1020200091131-A/4: COMPOSITION FOR ANTICANCER IMMUNE VACCINE USING RNA OLIGONUCLEOTIDE
CGTTTGCC
>OF011327.1 KR 1020200091131-A/3: COMPOSITION FOR ANTICANCER IMMUNE VACCINE USING RNA OLIGONUCLEOTIDE
GGTAGACG
>OF011326.1 KR 1020200091131-A/2: COMPOSITION FOR ANTICANCER IMMUNE VACCINE USING RNA OLIGONUCLEOTIDE
NNTTTGCN
>OF011325.1 KR 1020200091131-A/1: COMPOSITION FOR ANTICANCER IMMUNE VACCINE USING RNA OLIGONUCLEOTIDE
NGTAGANN
>OF092513.1 KR 1020200111726-A/124: CLOSED-ENDED DNA VECTORS OBTAINABLE FROM CELL-FREE SYNTHESIS AND PROCESS FOR OBTAINING CEDNA VECTORS
TTAATTAA
>OF092512.1 KR 1020200111726-A/123: CLOSED-ENDED DNA VECTORS OBTAINABLE FROM CELL-FREE SYNTHESIS AND PROCESS FOR OBTAINING CEDNA VECTORS
GTTTAAAC
>OF092478.1 KR 1020200111726-A/70: CLOSED-ENDED DNA VECTORS OBTAINABLE FROM CELL-FREE SYNTHESIS AND PROCESS FOR OBTAINING CEDNA VECTORS
GCCTCAGT
>OF092477.1 KR 1020200111726-A/69: CLOSED-ENDED DNA VECTORS OBTAINABLE FROM CELL-FREE SYNTHESIS AND PROCESS FOR OBTAINING CEDNA VECTORS
ACTGAGGC
>OF092317.1 KR 1020200110376-A/46: ADENO-ASSOCIATED VIRUS GENE THERAPY FOR 21-HYDROXYLASE DEFICIENCY
CCACCATG
>OF129408.1 KR 1020200133284-A/38: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
GCTGGCAG
>OF044363.1 KR 1020200093635-A/542: GENE EDITING USING A MODIFIED CLOSED-ENDED DNA (CEDNA)
TTAATTAA
>OF044357.1 KR 1020200093635-A/535: GENE EDITING USING A MODIFIED CLOSED-ENDED DNA (CEDNA)
GCCTCAGT
>OF044356.1 KR 1020200093635-A/532: GENE EDITING USING A MODIFIED CLOSED-ENDED DNA (CEDNA)
ACTGAGGC
>OF044221.1 KR 1020200093635-A/7: GENE EDITING USING A MODIFIED CLOSED-ENDED DNA (CEDNA)
GTTTAAAC
>OF117410.1 KR 1020200120956-A/30: CULTURE MEDIA FOR STEM CELLS
ACTCCCAG
>OF117407.1 KR 1020200120956-A/27: CULTURE MEDIA FOR STEM CELLS
GGATGGAG
>OF117404.1 KR 1020200120956-A/24: CULTURE MEDIA FOR STEM CELLS
TGGTGGAG
>OF117401.1 KR 1020200120956-A/21: CULTURE MEDIA FOR STEM CELLS
GGTGGTGG
>OF117396.1 KR 1020200120956-A/16: CULTURE MEDIA FOR STEM CELLS
TTGCCCAG
>OF117393.1 KR 1020200120956-A/13: CULTURE MEDIA FOR STEM CELLS
AGGAGCAG
>OF117390.1 KR 1020200120956-A/10: CULTURE MEDIA FOR STEM CELLS
CCTCCTGG
>OF117387.1 KR 1020200120956-A/7: CULTURE MEDIA FOR STEM CELLS
TGGCTCTG
>OF117384.1 KR 1020200120956-A/4: CULTURE MEDIA FOR STEM CELLS
GCAGCCAG
>OF115417.1 KR 1020200131260-A/11: METHODS AND COMPOSITIONS FOR DECREASING SOLUBLE IMMUNE RECEPTOR CD28
AAAGGTGA
>OF035415.1 KR 1020200095479-A/2: VACCINATION WITH REPLICON PARTICLES AND OIL ADJUVANT
TTAATTAA
>OF026675.1 KR 1020200096893-A/26: Nucleic acid complex pair, competitive structure, PCR kit using the same
AACCTTGG
>OF026669.1 KR 1020200096893-A/20: Nucleic acid complex pair, competitive structure, PCR kit using the same
CGCGCGGG
>OF026668.1 KR 1020200096893-A/19: Nucleic acid complex pair, competitive structure, PCR kit using the same
CCCGCGCG
>OF026652.1 KR 1020200096893-A/3: Nucleic acid complex pair, competitive structure, PCR kit using the same
TTTTTTTT
>OF026650.1 KR 1020200096893-A/1: Nucleic acid complex pair, competitive structure, PCR kit using the same
AAAAAAAA
>pdb|1P3X|A Chain A, INTRAMOLECULAR DNA TRIPLEX WITH 1-PROPYNYL DEOXYURIDINE IN THE THIRD STRAND, NMR, 10 STRUCTURES
AGAGAGAA
>pdb|7OMA|K Chain K, Thosea asigna virus RdRP domain elongation complex
NAAAATTT
>pdb|7OMA|J Chain J, Thosea asigna virus RdRP domain elongation complex
NAAAATTT
>pdb|7OMA|H Chain H, Thosea asigna virus RdRP domain elongation complex
NAAAATTT
>pdb|7OMA|F Chain F, Thosea asigna virus RdRP domain elongation complex
NAAAATTT
>pdb|7OM7|L Chain L, Thosea asigna virus RdRP domain in complex with RNA and nucleotide UMPNPP
CAAAATTT
>pdb|7OM7|K Chain K, Thosea asigna virus RdRP domain in complex with RNA and nucleotide UMPNPP
NAAAATTT
>pdb|7OM7|J Chain J, Thosea asigna virus RdRP domain in complex with RNA and nucleotide UMPNPP
CAAAATTT
>pdb|7OM7|I Chain I, Thosea asigna virus RdRP domain in complex with RNA and nucleotide UMPNPP
NAAAATTT
>pdb|7OM7|H Chain H, Thosea asigna virus RdRP domain in complex with RNA and nucleotide UMPNPP
NAAAATTT
>pdb|7OM7|G Chain G, Thosea asigna virus RdRP domain in complex with RNA and nucleotide UMPNPP
CAAAATTT
>pdb|7OM7|F Chain F, Thosea asigna virus RdRP domain in complex with RNA and nucleotide UMPNPP
NAAAATTT
>pdb|7OM7|E Chain E, Thosea asigna virus RdRP domain in complex with RNA and nucleotide UMPNPP
CAAAATTT
>pdb|7OM6|F Chain F, Thosea asigna virus RdRP domain in complex with RNA
NAAAATTT
>pdb|7OM6|E Chain E, Thosea asigna virus RdRP domain in complex with RNA
NAAAATTT
>pdb|7OM6|D Chain D, Thosea asigna virus RdRP domain in complex with RNA
CAAAATTT
>pdb|7OM6|C Chain C, Thosea asigna virus RdRP domain in complex with RNA
CAAAATTT
>pdb|7EL1|D Chain D, Structure of a protein from bacteria
TTGAATAG
>pdb|7OGK|D Chain D, A cooperative PNPase-Hfq-RNA carrier complex facilitates bacterial riboregulation. PNPase-3'ETS(leuZ)
NAAAAAAA
>pdb|1P3X|B Chain B, INTRAMOLECULAR DNA TRIPLEX WITH 1-PROPYNYL DEOXYURIDINE IN THE THIRD STRAND, NMR, 10 STRUCTURES
TTCTCTCT
>MQ110951.1 Sequence 8 from Patent WO2021133916
TGATGCGG
>MQ105227.1 Sequence 39 from Patent WO2021123074
ACACCAAC
>MQ105226.1 Sequence 38 from Patent WO2021123074
AGACGCAC
>MQ105225.1 Sequence 37 from Patent WO2021123074
CAGGAGCA
>MQ105223.1 Sequence 35 from Patent WO2021123074
ACACCAAC
>MQ105199.1 Sequence 11 from Patent WO2021123074
GTTGGTGT
>MQ105198.1 Sequence 10 from Patent WO2021123074
GTGCGTCT
>MQ105197.1 Sequence 9 from Patent WO2021123074
TGCTCCTG
>MQ105195.1 Sequence 7 from Patent WO2021123074
GTTGGTGT
>pdb|7M85|P Chain P, Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 80 s
AGCGTCAA
>pdb|7M84|P Chain P, Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 40 s
AGCGTCAA
>pdb|7M83|P Chain P, Human DNA Pol eta S113A with dA-ended primer and dATP: in crystallo reaction for 0 s
AGCGTCAA
>pdb|7M7Y|P Chain P, Human DNA Pol eta with dA-ended primer and dATP: in crystallo reaction for 0 s
AGCGTCAA
>pdb|7M7U|P Chain P, Human DNA Pol eta S113A with dT-ended primer and dATP: in crystallo reaction for 480s
AGCGTCAT
>pdb|7M7T|P Chain P, Human DNA Pol eta S113A with dT-ended primer and dATP: in crystallo reaction for 0 s
AGCGTCAT
>pdb|7M7N|P Chain P, Human DNA Pol eta with 2'-FA-ended primer and dAMPNPP
AGCGTCAN
>pdb|7M7L|P Chain P, Human DNA Pol eta with dA-ended primer and dAMPNPP
AGCGTCAA
>PA259878.1 WO 2021039824-A/13: RNA methyltransferase inhibitor and screening method thereof
ACATTCCA
>OG174126.1 JP 2021040506-A/11: An expression vector and a method for producing target protein
TTAATCGC
>MQ069899.1 Sequence 1 from Patent WO2021105857
GSSGGSSG
>MQ064165.1 Sequence 4 from Patent EP3826643
TCACATGG
>MQ063918.1 Sequence 20 from Patent EP3827084
CGGCTATT
>MQ063917.1 Sequence 19 from Patent EP3827084
AATAGCCG
>pdb|6WK6|P Chain P, Crystal structure of human polymerase eta complexed with Xanthine containing DNA
AGTGTGAG
>MQ052626.1 Sequence 205 from Patent WO2021096605
TACTAACA
>MQ051746.1 Sequence 112 from Patent WO2021094752
TAGCTATG
>MQ051745.1 Sequence 111 from Patent WO2021094752
TAGATATG
>MQ051744.1 Sequence 110 from Patent WO2021094752
GAGCTATG
>MQ051743.1 Sequence 109 from Patent WO2021094752
GAGATATG
>MQ051730.1 Sequence 96 from Patent WO2021094752
TGGTRAGT
>MQ051726.1 Sequence 92 from Patent WO2021094752
TAGGGATG
>MQ051725.1 Sequence 91 from Patent WO2021094752
TAGGCATG
>MQ051724.1 Sequence 90 from Patent WO2021094752
TAGGAATG
>MQ051723.1 Sequence 89 from Patent WO2021094752
TAGCGATG
>MQ051722.1 Sequence 88 from Patent WO2021094752
TAGCCATG
>MQ051721.1 Sequence 87 from Patent WO2021094752
TAGCAATG
>MQ051720.1 Sequence 86 from Patent WO2021094752
TAGAGATG
>MQ051719.1 Sequence 85 from Patent WO2021094752
TAGACATG
>MQ051718.1 Sequence 84 from Patent WO2021094752
TAGAAATG
>MQ051717.1 Sequence 83 from Patent WO2021094752
GAGGGATG
>MQ051716.1 Sequence 82 from Patent WO2021094752
GAGGCATG
>MQ051715.1 Sequence 81 from Patent WO2021094752
GAGGAATG
>MQ051714.1 Sequence 80 from Patent WO2021094752
GAGCGATG
>MQ051713.1 Sequence 79 from Patent WO2021094752
GAGCCATG
>MQ051712.1 Sequence 78 from Patent WO2021094752
GAGCAATG
>MQ051711.1 Sequence 77 from Patent WO2021094752
GAGAGATG
>MQ051710.1 Sequence 76 from Patent WO2021094752
GAGACATG
>MQ051709.1 Sequence 75 from Patent WO2021094752
GAGAAATG
>MQ051665.1 Sequence 31 from Patent WO2021094752
KAGVVATG
>MQ049091.1 Sequence 9 from Patent WO2021097255
GCGGCCCG
>OG170242.1 WO 2021025104-A/23: Plant RNA
TTCTTCTT
>OG170232.1 WO 2021025104-A/13: Plant RNA
TCTTCTTC
>OG170222.1 WO 2021025104-A/3: Plant RNA
CTTCTTCT
>OG168242.1 JP 2021023222-A/23: Plant RNA
TTCTTCTT
>OG168232.1 JP 2021023222-A/13: Plant RNA
TCTTCTTC
>OG168222.1 JP 2021023222-A/3: Plant RNA
CTTCTTCT
>OG167368.1 JP 2021024792-A/20: agent and method for promoting muscle differentiation, and oligodeoxynucleotide for promoting muscle differentiation
GGGWGGGG
>OG167352.1 JP 2021024792-A/4: agent and method for promoting muscle differentiation, and oligodeoxynucleotide for promoting muscle differentiation
GGGTGGGG
>pdb|7NUQ|C Chain C, Rhinovirus 14 virion-like at pH 6.2
NGTTTTTA
>pdb|7NUN|C Chain C, Rhinovirus 14 ICAM-1 virion-like particle at pH 6.2
NGTTTTTA
>pdb|7BG6|C Chain C, HRV14 native particle solved by cryoEM
NGTTTTTA
>MQ038084.1 Sequence 17 from Patent WO2021087084
CGCGCGCG
>MQ037962.1 Sequence 11 from Patent WO2021084277
TTAAATAC
>MQ032300.1 Sequence 743 from Patent EP3814510
TGGATTTG
>MQ032299.1 Sequence 742 from Patent EP3814510
TGCTGCTG
>MQ032298.1 Sequence 741 from Patent EP3814510
AATCTGAC
>MQ032297.1 Sequence 740 from Patent EP3814510
GCTGCATT
>MQ032296.1 Sequence 739 from Patent EP3814510
GTGTCTGT
>MQ032295.1 Sequence 738 from Patent EP3814510
CACCATCA
>MQ032294.1 Sequence 737 from Patent EP3814510
GCCATGGC
>MQ032293.1 Sequence 736 from Patent EP3814510
TCGTAATC
>MQ032292.1 Sequence 735 from Patent EP3814510
CTAGGACT
>MQ032291.1 Sequence 734 from Patent EP3814510
CAGAAGAT
>MQ032290.1 Sequence 733 from Patent EP3814510
GGAAAATC
>MQ032289.1 Sequence 732 from Patent EP3814510
TCGCTTTC
>MQ031701.1 Sequence 144 from Patent EP3814510
CGAGGTGT
>MQ031691.1 Sequence 134 from Patent EP3814510
GGCTCTTA
>MQ031667.1 Sequence 110 from Patent EP3814510
CTCAAACA
>MQ031627.1 Sequence 70 from Patent EP3814510
CGACGAGG
>MQ031587.1 Sequence 30 from Patent EP3814510
TTCACAGA
>MP987023.1 Sequence 42 from Patent WO2021058734
CTCTCCTC
>MP987022.1 Sequence 41 from Patent WO2021058734
CCTCCCTT
>pdb|6ZM2|B Chain B, Crystal structure of the DEAH-box ATPase Prp2 in complex with ADP-BeF3 and ssRNA
NTTTTTTT
>pdb|7NEJ|B Chain B, Solution structure of DNA:RNA hybrid duplex
CCGTGTAG
>pdb|7NEJ|A Chain A, Solution structure of DNA:RNA hybrid duplex
CTACACGG
>pdb|7NBL|B Chain B, Solution structure of DNA:RNA hybrid containing a 2'-deoxy-2'2'-difluorodeoxycytidine (gemcitabine) modification
CCGTGTAG
>pdb|7NBL|A Chain A, Solution structure of DNA:RNA hybrid containing a 2'-deoxy-2'2'-difluorodeoxycytidine (gemcitabine) modification
CTANACGG
>pdb|7E4E|A Chain A, NMR solution structures of DNA minidumbbell containing a N1-methyladenine
TTTNTTTA
>pdb|6Z6B|XXX Chain XXX, Structure of full-length La Crosse virus L protein (polymerase)
GCTACTAA
>pdb|6Z6B|DDD Chain DDD, Structure of full-length La Crosse virus L protein (polymerase)
GCTACTAA
>pdb|6W5X|P Chain P, Crystal structure of human polymerase eta complexed with N7-benzylguanine and dCTP*
AGTGTGAG
>MP838668.1 Sequence 1 from Patent EP3740604
CCCTCCTC
>MP728569.1 Sequence 15 from Patent EP3684378
TCCCCTCT
>MP724131.1 Sequence 77 from Patent WO2020128015
TGACGTCA
>MP724107.1 Sequence 53 from Patent WO2020128015
TCACACCT
>MP724089.1 Sequence 34 from Patent WO2020128015
TTACGTAA
>MP724065.1 Sequence 10 from Patent WO2020128015
TGACGTCA
>MP827402.1 Sequence 163 from Patent WO2020223634
TTTTTTTT
>MP827400.1 Sequence 161 from Patent WO2020223634
TTATTATT
>MP827393.1 Sequence 154 from Patent WO2020223634
TTTTTTTT
>MP824996.1 Sequence 13 from Patent WO2020223541
CTGCTTCC
>MP925196.1 Sequence 251 from Patent WO2021023853
GTCTGCCG
>MP925195.1 Sequence 250 from Patent WO2021023853
ATTGGAGC
>MP925194.1 Sequence 249 from Patent WO2021023853
TAGGCGCG
>MP925193.1 Sequence 248 from Patent WO2021023853
TCCACACT
>MP925192.1 Sequence 247 from Patent WO2021023853
TCGAACCG
>MP925191.1 Sequence 246 from Patent WO2021023853
GATCTGAG
>MP925190.1 Sequence 245 from Patent WO2021023853
CCGCTCAG
>MP925189.1 Sequence 244 from Patent WO2021023853
TGCGACAT
>MP925188.1 Sequence 243 from Patent WO2021023853
GTGTTAGC
>MP925187.1 Sequence 242 from Patent WO2021023853
TCGCTACA
>MP925186.1 Sequence 241 from Patent WO2021023853
AACATTCT
>MP925185.1 Sequence 240 from Patent WO2021023853
CCGGCGTC
>MP925184.1 Sequence 239 from Patent WO2021023853
TAGTGAAC
>MP925183.1 Sequence 238 from Patent WO2021023853
CTAATGCG
>MP925182.1 Sequence 237 from Patent WO2021023853
CGGCGTGG
>MP925181.1 Sequence 236 from Patent WO2021023853
TGCTCTCA
>MP925180.1 Sequence 235 from Patent WO2021023853
TAGACTAT
>MP925179.1 Sequence 234 from Patent WO2021023853
AGAGATCT
>MP925178.1 Sequence 233 from Patent WO2021023853
GAATGAGT
>MP925158.1 Sequence 213 from Patent WO2021023853
AAGGATGT
>MP925157.1 Sequence 212 from Patent WO2021023853
TCGGAATG
>MP925156.1 Sequence 211 from Patent WO2021023853
CACATCCT
>MP925155.1 Sequence 210 from Patent WO2021023853
AACTTGAC
>MP925154.1 Sequence 209 from Patent WO2021023853
TTCGCTGA
>MP925153.1 Sequence 208 from Patent WO2021023853
GTATAACA
>MP925152.1 Sequence 207 from Patent WO2021023853
GGTCCAGA
>MP925151.1 Sequence 206 from Patent WO2021023853
ACCAACTG
>MP925150.1 Sequence 205 from Patent WO2021023853
TTGAGCCT
>MP925149.1 Sequence 204 from Patent WO2021023853
CCAGTTAG
>MP925148.1 Sequence 203 from Patent WO2021023853
AGTTGCTT
>MP925147.1 Sequence 202 from Patent WO2021023853
AGCAATTC
>MP925146.1 Sequence 201 from Patent WO2021023853
TGCTCGAC
>MP925145.1 Sequence 200 from Patent WO2021023853
GCACATCT
>MP925144.1 Sequence 199 from Patent WO2021023853
CATGCTTA
>MP925143.1 Sequence 198 from Patent WO2021023853
CTACCAGG
>MP925042.1 Sequence 97 from Patent WO2021023853
GCATTTGG
>MP925041.1 Sequence 96 from Patent WO2021023853
GCAGAGAA
>MP925040.1 Sequence 95 from Patent WO2021023853
ACGTTGTA
>MP925039.1 Sequence 94 from Patent WO2021023853
GAAAGGTG
>MP925038.1 Sequence 93 from Patent WO2021023853
TAAGGTCC
>MP925037.1 Sequence 92 from Patent WO2021023853
ACCGCTAA
>MP925036.1 Sequence 91 from Patent WO2021023853
CACTTATC
>MP925035.1 Sequence 90 from Patent WO2021023853
TACGCCTC
>MP925034.1 Sequence 89 from Patent WO2021023853
TGTTAAGC
>MP925033.1 Sequence 88 from Patent WO2021023853
ATATTCCC
>MP925032.1 Sequence 87 from Patent WO2021023853
GGGACAAC
>MP925031.1 Sequence 86 from Patent WO2021023853
TCTTGCTG
>MP925030.1 Sequence 85 from Patent WO2021023853
CATAGTCG
>MP925029.1 Sequence 84 from Patent WO2021023853
AGTCTGCC
>MP925028.1 Sequence 83 from Patent WO2021023853
CGCTTGCT
>MP925027.1 Sequence 82 from Patent WO2021023853
TTAGACGC
>MP925026.1 Sequence 81 from Patent WO2021023853
TGAGCATA
>MP925025.1 Sequence 80 from Patent WO2021023853
TTTGTGTC
>MP925024.1 Sequence 79 from Patent WO2021023853
ACAGGCAT
>MP925023.1 Sequence 78 from Patent WO2021023853
CCACAACT
>MP925022.1 Sequence 77 from Patent WO2021023853
AGGTAAAG
>MP925021.1 Sequence 76 from Patent WO2021023853
GCTTCCCT
>MP925020.1 Sequence 75 from Patent WO2021023853
AATCATGC
>MP925019.1 Sequence 74 from Patent WO2021023853
ATTCCTAG
>MP925018.1 Sequence 73 from Patent WO2021023853
CATGGGTT
>MP925017.1 Sequence 72 from Patent WO2021023853
ACCTGGAG
>MP925016.1 Sequence 71 from Patent WO2021023853
GACGCAAT
>MP925015.1 Sequence 70 from Patent WO2021023853
CCGAGTAC
>MP925014.1 Sequence 69 from Patent WO2021023853
CGGAAGTG
>MP925013.1 Sequence 68 from Patent WO2021023853
GTAACTCC
>MP925012.1 Sequence 67 from Patent WO2021023853
ACTAGCGA
>MP925011.1 Sequence 66 from Patent WO2021023853
CGTGATTC
>MP925010.1 Sequence 65 from Patent WO2021023853
AGGACTTA
>MP925009.1 Sequence 64 from Patent WO2021023853
TCTATGGT
>MP925008.1 Sequence 63 from Patent WO2021023853
GCATAATC
>MP925007.1 Sequence 62 from Patent WO2021023853
GCCATCTT
>MP925006.1 Sequence 61 from Patent WO2021023853
CGGGTGAA
>MP925005.1 Sequence 60 from Patent WO2021023853
GAGGGTAG
>MP925004.1 Sequence 59 from Patent WO2021023853
ATGCGACG
>MP925003.1 Sequence 58 from Patent WO2021023853
CCATGGGA
>MP925002.1 Sequence 57 from Patent WO2021023853
CAACTAGA
>MP925001.1 Sequence 56 from Patent WO2021023853
TCTGGGCA
>MP925000.1 Sequence 55 from Patent WO2021023853
GAAGACTT
>MP924999.1 Sequence 54 from Patent WO2021023853
TTCGCTGT
>MP924998.1 Sequence 53 from Patent WO2021023853
TGATGTAG
>MP924997.1 Sequence 52 from Patent WO2021023853
GGGATTGT
>MP924996.1 Sequence 51 from Patent WO2021023853
CTACGCTG
>MP924995.1 Sequence 50 from Patent WO2021023853
GTCCTATA
>MP924994.1 Sequence 49 from Patent WO2021023853
CTGTCATT
>MP924993.1 Sequence 48 from Patent WO2021023853
AAGCACAT
>MP924992.1 Sequence 47 from Patent WO2021023853
AGTTGTGT
>MP924991.1 Sequence 46 from Patent WO2021023853
TTCGGAAA
>MP924990.1 Sequence 45 from Patent WO2021023853
ACGTATCC
>MP924989.1 Sequence 44 from Patent WO2021023853
GGATTGAC
>MP924988.1 Sequence 43 from Patent WO2021023853
GTAGAACG
>MP924987.1 Sequence 42 from Patent WO2021023853
ACACCGTG
>MP924986.1 Sequence 41 from Patent WO2021023853
TAACTCCG
>MP924985.1 Sequence 40 from Patent WO2021023853
GACAAACC
>MP924984.1 Sequence 39 from Patent WO2021023853
GGTGGACT
>MP924983.1 Sequence 38 from Patent WO2021023853
ACCTCAGC
>MP924982.1 Sequence 37 from Patent WO2021023853
CCAGTCCA
>MP924981.1 Sequence 36 from Patent WO2021023853
GGTAATCA
>MP924980.1 Sequence 35 from Patent WO2021023853
AGCCACCA
>MP924979.1 Sequence 34 from Patent WO2021023853
AACGAGGT
>MP924978.1 Sequence 33 from Patent WO2021023853
TGTACCAA
>MP924977.1 Sequence 32 from Patent WO2021023853
GTTGCCAC
>MP924976.1 Sequence 31 from Patent WO2021023853
TCACCCGA
>MP924975.1 Sequence 30 from Patent WO2021023853
AGCTCCTT
>MP924974.1 Sequence 29 from Patent WO2021023853
GTCATTAG
>MP924973.1 Sequence 28 from Patent WO2021023853
GTGCATGA
>MP924972.1 Sequence 27 from Patent WO2021023853
CGCAAAGT
>MP924971.1 Sequence 26 from Patent WO2021023853
CTGTACAA
>MP924970.1 Sequence 25 from Patent WO2021023853
AAGTGGCT
>MP924969.1 Sequence 24 from Patent WO2021023853
ACTGTTTG
>MP924968.1 Sequence 23 from Patent WO2021023853
TTCCGTTC
>MP924967.1 Sequence 22 from Patent WO2021023853
GGACCTTT
>MP924966.1 Sequence 21 from Patent WO2021023853
GTTACAGG
>MP924965.1 Sequence 20 from Patent WO2021023853
CACACTGA
>MP924964.1 Sequence 19 from Patent WO2021023853
GAGTCCTG
>MP924963.1 Sequence 18 from Patent WO2021023853
CCTTCAAG
>MP924962.1 Sequence 17 from Patent WO2021023853
CTTTGACA
>MP924961.1 Sequence 16 from Patent WO2021023853
CACAGCAT
>MP924960.1 Sequence 15 from Patent WO2021023853
TTACGGGT
>MP924959.1 Sequence 14 from Patent WO2021023853
GATGTCGA
>MP924958.1 Sequence 13 from Patent WO2021023853
ACGATAGG
>MP924957.1 Sequence 12 from Patent WO2021023853
TACTGGTA
>MP924956.1 Sequence 11 from Patent WO2021023853
TCTCACAC
>MP924955.1 Sequence 10 from Patent WO2021023853
TGAATACC
>MP924954.1 Sequence 9 from Patent WO2021023853
TGGAGCTC
>MP924953.1 Sequence 8 from Patent WO2021023853
TGCGTAGG
>MP924952.1 Sequence 7 from Patent WO2021023853
ATACAGAC
>MP924951.1 Sequence 6 from Patent WO2021023853
ATTTAGCG
>MP924950.1 Sequence 5 from Patent WO2021023853
TCAACGAC
>MP924949.1 Sequence 4 from Patent WO2021023853
GCACGTCA
>MP924948.1 Sequence 3 from Patent WO2021023853
AGACTCGT
>MP924947.1 Sequence 2 from Patent WO2021023853
CGTCTAAT
>MP713855.1 Sequence 12 from Patent WO2020126595
CTTCGCTT
>MP713854.1 Sequence 11 from Patent WO2020126595
GCCTCTAT
>MP713853.1 Sequence 10 from Patent WO2020126595
AGGCTATA
>MP713852.1 Sequence 9 from Patent WO2020126595
GATCTGCT
>MP713851.1 Sequence 8 from Patent WO2020126595
ACGAATAA
>MP713850.1 Sequence 7 from Patent WO2020126595
TTATGAGT
>MP713848.1 Sequence 5 from Patent WO2020126595
TCAGAGCC
>MP713847.1 Sequence 4 from Patent WO2020126595
AGGATAGG
>MP713245.1 Sequence 542 from Patent EP3678710
TTAATTAA
>MP713238.1 Sequence 535 from Patent EP3678710
GCCTCAGT
>MP713235.1 Sequence 532 from Patent EP3678710
ACTGAGGC
>MP712764.1 Sequence 7 from Patent EP3678710
GTTTAAAC
>MP711291.1 Sequence 542 from Patent EP3679148
TTAATTAA
>MP711212.1 Sequence 7 from Patent EP3679148
GTTTAAAC
>MP918921.1 Sequence 12 from Patent EP3781695
TCCCCCCT
>MP816139.1 Sequence 6 from Patent WO2020212650
TCCACTGC
>MP802097.1 Sequence 129 from Patent WO2020208017
TATAAAGC
>MP696997.1 Sequence 21 from Patent EP3673065
CNCACCNG
>MP696986.1 Sequence 10 from Patent EP3673065
CACCNGGA
>MP908407.1 Sequence 150 from Patent WO2021019197
TTAAGCCA
>MP908406.1 Sequence 149 from Patent WO2021019197
CTAGTAGG
>MP908405.1 Sequence 148 from Patent WO2021019197
ACTAATGC
>MP908404.1 Sequence 147 from Patent WO2021019197
TGCCGATT
>MP908403.1 Sequence 146 from Patent WO2021019197
GTCGAATT
>MP908402.1 Sequence 145 from Patent WO2021019197
ATCACAAG
>MP908401.1 Sequence 144 from Patent WO2021019197
ACAGCTGT
>MP908400.1 Sequence 143 from Patent WO2021019197
ATCGACAT
>MP908399.1 Sequence 142 from Patent WO2021019197
TTCGACTC
>MP908398.1 Sequence 141 from Patent WO2021019197
AGCTGTTG
>MP908397.1 Sequence 140 from Patent WO2021019197
ATTCCGAT
>MP908396.1 Sequence 139 from Patent WO2021019197
CAATGGTA
>MP908395.1 Sequence 138 from Patent WO2021019197
AGTGCGAA
>MP908394.1 Sequence 137 from Patent WO2021019197
AGCTATAT
>MP908393.1 Sequence 136 from Patent WO2021019197
ACGTTCAG
>MP908392.1 Sequence 135 from Patent WO2021019197
GACGTATC
>MP908391.1 Sequence 134 from Patent WO2021019197
AAGTAGTC
>MP908390.1 Sequence 133 from Patent WO2021019197
TACGTTAA
>MP908389.1 Sequence 132 from Patent WO2021019197
CTAGCGAT
>MP908388.1 Sequence 131 from Patent WO2021019197
CTTCGCAT
>MP908387.1 Sequence 130 from Patent WO2021019197
CACTAGAT
>MP908386.1 Sequence 129 from Patent WO2021019197
TATTCTCG
>MP908385.1 Sequence 128 from Patent WO2021019197
GACTTCCA
>MP908384.1 Sequence 127 from Patent WO2021019197
TGTGCCAT
>MP908383.1 Sequence 126 from Patent WO2021019197
TAAGTCTG
>MP908382.1 Sequence 125 from Patent WO2021019197
CAGAATAT
>MP908381.1 Sequence 124 from Patent WO2021019197
ATGTGTCT
>MP908380.1 Sequence 123 from Patent WO2021019197
TCAGTAGA
>MP908379.1 Sequence 122 from Patent WO2021019197
CGTGATTA
>MP908378.1 Sequence 121 from Patent WO2021019197
AGTCGTTA
>MP908377.1 Sequence 120 from Patent WO2021019197
GACTTAGG
>MP908376.1 Sequence 119 from Patent WO2021019197
GATAGCAC
>MP908375.1 Sequence 118 from Patent WO2021019197
ACTACATG
>MP908374.1 Sequence 117 from Patent WO2021019197
TAGCTCTT
>MP908373.1 Sequence 116 from Patent WO2021019197
TCATGATG
>MP908372.1 Sequence 115 from Patent WO2021019197
CAAGTAAT
>MP908371.1 Sequence 114 from Patent WO2021019197
TAGCAACA
>MP908370.1 Sequence 113 from Patent WO2021019197
AAGACTAG
>MP908369.1 Sequence 112 from Patent WO2021019197
ATAAGGCC
>MP908368.1 Sequence 111 from Patent WO2021019197
GCTGATTC
>MP908367.1 Sequence 110 from Patent WO2021019197
TTATACCG
>MP908366.1 Sequence 109 from Patent WO2021019197
TCATCAGC
>MP908365.1 Sequence 108 from Patent WO2021019197
CTGGATAG
>MP908364.1 Sequence 107 from Patent WO2021019197
ATACAGCG
>MP908363.1 Sequence 106 from Patent WO2021019197
GATACAAG
>MP908362.1 Sequence 105 from Patent WO2021019197
CTTGTTGA
>MP908361.1 Sequence 104 from Patent WO2021019197
TAATGCTC
>MP908360.1 Sequence 103 from Patent WO2021019197
TGCTAACG
>MP908359.1 Sequence 102 from Patent WO2021019197
TGGTAAGC
>MP908358.1 Sequence 101 from Patent WO2021019197
ACGTTACA
>MP908357.1 Sequence 100 from Patent WO2021019197
GAGTACAC
>MP908356.1 Sequence 99 from Patent WO2021019197
TCTTACTG
>MP908355.1 Sequence 98 from Patent WO2021019197
TTGATCTC
>MP908354.1 Sequence 97 from Patent WO2021019197
CTTAGGTG
>MP908353.1 Sequence 96 from Patent WO2021019197
TAATCGCT
>MP908352.1 Sequence 95 from Patent WO2021019197
TTCAGGTC
>MP908351.1 Sequence 94 from Patent WO2021019197
GATCATGA
>MP908350.1 Sequence 93 from Patent WO2021019197
ACTGTAAG
>MP908349.1 Sequence 92 from Patent WO2021019197
GTACACGA
>MP908348.1 Sequence 91 from Patent WO2021019197
AGTTACAC
>MP908347.1 Sequence 90 from Patent WO2021019197
TGTACTAA
>MP908346.1 Sequence 89 from Patent WO2021019197
GCTAGAAT
>MP908345.1 Sequence 88 from Patent WO2021019197
GGCTAATA
>MP908344.1 Sequence 87 from Patent WO2021019197
TGTTGGCA
>MP908343.1 Sequence 86 from Patent WO2021019197
AGAACACT
>MP908342.1 Sequence 85 from Patent WO2021019197
GAACGTCT
>MP908341.1 Sequence 84 from Patent WO2021019197
AGTTAGCG
>MP908340.1 Sequence 83 from Patent WO2021019197
CGTAGGAT
>MP908339.1 Sequence 82 from Patent WO2021019197
AAGCGTCA
>MP908338.1 Sequence 81 from Patent WO2021019197
TTCATTCG
>MP908337.1 Sequence 80 from Patent WO2021019197
GTTCTACA
>MP908336.1 Sequence 79 from Patent WO2021019197
ATTGTCAA
>MP908335.1 Sequence 78 from Patent WO2021019197
AATAGGCA
>MP908334.1 Sequence 77 from Patent WO2021019197
CCGGAATA
>MP908333.1 Sequence 76 from Patent WO2021019197
AAGTGAGC
>MP908332.1 Sequence 75 from Patent WO2021019197
TAGGCGTA
>MP908331.1 Sequence 74 from Patent WO2021019197
TGACGTTC
>MP908330.1 Sequence 73 from Patent WO2021019197
GCGTTAGT
>MP908329.1 Sequence 72 from Patent WO2021019197
GTTACACC
>MP908328.1 Sequence 71 from Patent WO2021019197
CACCAGTA
>MP908327.1 Sequence 70 from Patent WO2021019197
AGACTAAC
>MP908326.1 Sequence 69 from Patent WO2021019197
TTGTATTC
>MP908325.1 Sequence 68 from Patent WO2021019197
TCACTGTT
>MP908324.1 Sequence 67 from Patent WO2021019197
TGTCTATG
>MP908323.1 Sequence 66 from Patent WO2021019197
AATACCGC
>MP908322.1 Sequence 65 from Patent WO2021019197
TGTACATT
>MP908321.1 Sequence 64 from Patent WO2021019197
TCTAAGTT
>MP908320.1 Sequence 63 from Patent WO2021019197
GTTAAGAC
>MP908319.1 Sequence 62 from Patent WO2021019197
TAGTTGCC
>MP908318.1 Sequence 61 from Patent WO2021019197
TGACCTCA
>MP908317.1 Sequence 60 from Patent WO2021019197
AGCGTTAC
>MP908316.1 Sequence 59 from Patent WO2021019197
CGAATACA
>MP908315.1 Sequence 58 from Patent WO2021019197
AGAGGATC
>MP908314.1 Sequence 57 from Patent WO2021019197
TGGCTAAT
>MP908313.1 Sequence 56 from Patent WO2021019197
GGTCTCAA
>MP908312.1 Sequence 55 from Patent WO2021019197
TGGTACAG
>MP908311.1 Sequence 54 from Patent WO2021019197
AGCCTGAA
>MP908310.1 Sequence 53 from Patent WO2021019197
GATGCTCA
>MP908309.1 Sequence 52 from Patent WO2021019197
TGGAAGCA
>MP908308.1 Sequence 51 from Patent WO2021019197
TTCTGCTA
>MP908307.1 Sequence 50 from Patent WO2021019197
TTCGTACA
>MP908306.1 Sequence 49 from Patent WO2021019197
ACGCATGA
>MP908305.1 Sequence 48 from Patent WO2021019197
TAGTGTAC
>MP908304.1 Sequence 47 from Patent WO2021019197
CGAATGGT
>MP908303.1 Sequence 46 from Patent WO2021019197
CTGACAAT
>MP908302.1 Sequence 45 from Patent WO2021019197
CTTGGTAC
>MP908301.1 Sequence 44 from Patent WO2021019197
CTGAGCTT
>MP908300.1 Sequence 43 from Patent WO2021019197
TCGGAGAA
>MP908299.1 Sequence 42 from Patent WO2021019197
CACTGCAA
>MP908298.1 Sequence 41 from Patent WO2021019197
CTGATGTA
>MP908297.1 Sequence 40 from Patent WO2021019197
TCCTTCGA
>MP908296.1 Sequence 39 from Patent WO2021019197
CACATGCA
>MP908295.1 Sequence 38 from Patent WO2021019197
GCAATATA
>MP908294.1 Sequence 37 from Patent WO2021019197
TGGTCGAA
>MP908293.1 Sequence 36 from Patent WO2021019197
GTCACCAT
>MP908292.1 Sequence 35 from Patent WO2021019197
CAGATAGT
>MP908291.1 Sequence 34 from Patent WO2021019197
ACGCTTAT
>MP908290.1 Sequence 33 from Patent WO2021019197
TGAGTGAC
>MP908289.1 Sequence 32 from Patent WO2021019197
AGCTCTCA
>MP908288.1 Sequence 31 from Patent WO2021019197
CTCTAGCA
>MP900868.1 Sequence 115 from Patent EP3775217
CCAAGAGC
>MP900867.1 Sequence 114 from Patent EP3775217
GTACTTGG
>MP798213.1 Sequence 17 from Patent WO2020202162
TTCCGATC
>MP798202.1 Sequence 6 from Patent WO2020202162
TTCCGATC
>MP687434.1 Sequence 4 from Patent EP3664814
ACATTTTT
>MP898055.1 Sequence 44 from Patent WO2021021661
TCATTCTA
>MP894795.1 Sequence 102 from Patent EP3773649
TATTCCCG
>MP894794.1 Sequence 101 from Patent EP3773649
AGTGCCCG
>MP894704.1 Sequence 11 from Patent EP3773649
TGCCTTAA
>MP894701.1 Sequence 8 from Patent EP3773649
CAGTATGA
>MP894698.1 Sequence 5 from Patent EP3773649
TCACCAGG
>MP894697.1 Sequence 4 from Patent EP3773649
CTGACCTC
>MP681059.1 Sequence 9 from Patent WO2020112967
TTAGAGTA
>MP681058.1 Sequence 8 from Patent WO2020112967
ACTTAATG
>MP681057.1 Sequence 7 from Patent WO2020112967
TTAGAGTA
>MP787950.1 Sequence 13 from Patent WO2020191270
CTGCTTCC
>MP888924.1 Sequence 124 from Patent EP3759217
TTAATTAA
>MP888923.1 Sequence 123 from Patent EP3759217
GTTTAAAC
>MP888870.1 Sequence 70 from Patent EP3759217
GCCTCAGT
>MP888869.1 Sequence 69 from Patent EP3759217
ACTGAGGC
>MP672683.1 Sequence 26 from Patent EP3660171
AACCTTGG
>MP672677.1 Sequence 20 from Patent EP3660171
CGCGCGGG
>MP672676.1 Sequence 19 from Patent EP3660171
CCCGCGCG
>MP672660.1 Sequence 3 from Patent EP3660171
TTTTTTTT
>MP672658.1 Sequence 1 from Patent EP3660171
AAAAAAAA
>MP887229.1 Sequence 4 from Patent EP3765639
ATCCAGGG
>MP884616.1 Sequence 2 from Patent EP3765610
TGGCAGCT
>MP665788.1 Sequence 14 from Patent WO2020099533
ACACCAAC
>MP665787.1 Sequence 13 from Patent WO2020099533
GTTGGTGT
>MP665786.1 Sequence 12 from Patent WO2020099533
AGACGCAC
>MP665785.1 Sequence 11 from Patent WO2020099533
GTGCGTCT
>MP665782.1 Sequence 8 from Patent WO2020099533
CGTCAGGC
>MP665781.1 Sequence 7 from Patent WO2020099533
GCCTGACG
>MP665780.1 Sequence 6 from Patent WO2020099533
CAGGAGCA
>MP665779.1 Sequence 5 from Patent WO2020099533
TGCTCCTG
>MP964065.1 Sequence 516 from Patent EP3735460
CCGCCANG
>MP964064.1 Sequence 515 from Patent EP3735460
CCACCANG
>MP664168.1 Sequence 43 from Patent WO2020102565
AGGAGWDR
>MP664165.1 Sequence 40 from Patent WO2020102565
DGAATGAD
>MP664159.1 Sequence 34 from Patent WO2020102565
AAYGACRA
>MP664152.1 Sequence 27 from Patent WO2020102565
DGAATGAD
>MP664147.1 Sequence 22 from Patent WO2020102565
AGGAGWDR
>MP664145.1 Sequence 20 from Patent WO2020102565
GATAAACV
>MP664142.1 Sequence 17 from Patent WO2020102565
AGAGTATR
>MP664141.1 Sequence 16 from Patent WO2020102565
AGAGTATR
>MP761725.1 Sequence 3 from Patent EP3710594
TAGGTCAA
>MP761724.1 Sequence 2 from Patent EP3710594
TAGGCTTA
>MP761723.1 Sequence 1 from Patent EP3710594
ATGCTAGC
>MP662616.1 Sequence 66 from Patent WO2020104782
GTAAACAA
>MP661346.1 Sequence 59 from Patent WO2020104783
GTAAACAA
>MP756791.1 Sequence 229 from Patent EP3704239
TTTTTTTT
>MP865546.1 Sequence 94 from Patent WO2020165907
GGGTGGRR
>MP865534.1 Sequence 82 from Patent WO2020165907
GGGAGGRR
>MP862030.1 Sequence 25 from Patent WO2020245377
TTTTTTTT
>MP862019.1 Sequence 14 from Patent WO2020245377
ACACCAAC
>MP862018.1 Sequence 13 from Patent WO2020245377
GTTGGTGT
>MP862017.1 Sequence 12 from Patent WO2020245377
AGACGCAC
>MP862016.1 Sequence 11 from Patent WO2020245377
GTGCGTCT
>MP862009.1 Sequence 4 from Patent WO2020245377
CGTCAGGC
>MP862008.1 Sequence 3 from Patent WO2020245377
GCCTGACG
>MP862007.1 Sequence 2 from Patent WO2020245377
CAGGAGCA
>MP862006.1 Sequence 1 from Patent WO2020245377
TGCTCCTG
>MP643522.1 Sequence 22 from Patent EP3650546
CGTCATAC
>MP857966.1 Sequence 124 from Patent EP3752191
TTAATTAA
>MP857965.1 Sequence 123 from Patent EP3752191
GTTTAAAC
>MP857912.1 Sequence 70 from Patent EP3752191
GCCTCAGT
>MP857911.1 Sequence 69 from Patent EP3752191
ACTGAGGC
>MP746950.1 Sequence 4 from Patent EP3688190
ACGTCAGT
>MP746949.1 Sequence 3 from Patent EP3688190
ACTGACGT
>MP948293.1 Sequence 264 from Patent EP3755801
TGGTCATA
>MP948234.1 Sequence 205 from Patent EP3755801
TTAGGCGT
>MP948156.1 Sequence 127 from Patent EP3755801
GCTTCCTG
>MP948149.1 Sequence 120 from Patent EP3755801
CAAAACTC
>MP948127.1 Sequence 98 from Patent EP3755801
GCGAAATC
>MP948118.1 Sequence 89 from Patent EP3755801
TTAACCAG
>MP947132.1 Sequence 124 from Patent EP3755803
TTAATTAA
>MP947131.1 Sequence 123 from Patent EP3755803
GTTTAAAC
>MP947078.1 Sequence 70 from Patent EP3755803
GCCTCAGT
>MP947077.1 Sequence 69 from Patent EP3755803
ACTGAGGC
>MP843912.1 Sequence 87 from Patent EP3746461
TGNNNNTG
>MP736150.1 Sequence 40 from Patent WO2020148555
GATCGATC
>pdb|6XIQ|AY Chain AY, Cryo-EM Structure of K63R Ubiquitin Mutant Ribosome under Oxidative Stress
NAATTTTT
>pdb|6WHM|B Chain B, The crystal structure of the 2009/H1N1/California PA endonuclease wild type bound to DNA oligomer TAGC (cleaved TTAGCATT, 5mM overnight DNA soak)
TTAGCATT
>pdb|4V5J|CX Chain CX, Structure of the 70S ribosome bound to Release factor 2 and a substrate analog provides insights into catalysis of peptide release
AATTCTAA
>pdb|4V5J|AX Chain AX, Structure of the 70S ribosome bound to Release factor 2 and a substrate analog provides insights into catalysis of peptide release
AATTCTAA
>pdb|4V5E|CX Chain CX, Insights into translational termination from the structure of RF2 bound to the ribosome
AATTCTGA
>pdb|4V5E|AX Chain AX, Insights into translational termination from the structure of RF2 bound to the ribosome
AATTCTGA
>OG148631.1 JP 2019510511-A/75: NOVEL pRNA THREE-WAY JUNCTIONS
CCTCTTAC
>OG148630.1 JP 2019510511-A/74: NOVEL pRNA THREE-WAY JUNCTIONS
GTCACGGG
>OG143859.1 JP 2019511471-A/71: Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
CATACTTA
>OG143858.1 JP 2019511471-A/70: Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
CCAAAAGA
>OG143837.1 JP 2019511471-A/49: Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
CATACTTA
>OG143836.1 JP 2019511471-A/48: Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
CCAAAAGA
>OG156182.1 WO 2020171118-A/15: BIOLOGICAL CLOCK ACTIVATION DEVICE AND ITS CONTROL METHOD
TGACGTCA
>OF010308.1 KR 1020200074248-A/30: METHODS FOR TAGGING DNA-ENCODED LIBRARIES
CAGTGTCA
>OF010293.1 KR 1020200074248-A/15: METHODS FOR TAGGING DNA-ENCODED LIBRARIES
CAGACTGG
>OF010292.1 KR 1020200074248-A/14: METHODS FOR TAGGING DNA-ENCODED LIBRARIES
GTGAGTGC
>OF006212.1 KR 1020200067190-A/103: COMPOSITIONS AND METHODS FOR GENE EDITING FOR HEMOPHILIA A
NNNNGCTT
>OF006210.1 KR 1020200067190-A/101: COMPOSITIONS AND METHODS FOR GENE EDITING FOR HEMOPHILIA A
NNNNGATT
>OF003751.1 KR 1020200065025-A/6: NEW TREATMENT OF SMA
TTGATGGC
>pdb|5LZZ|hh Chain hh, Structure of the mammalian rescue complex with Pelota and Hbs1l (combined)
NCAAAGTT
>pdb|5LZY|hh Chain hh, Structure of the mammalian rescue complex with Pelota and Hbs1l assembled on a polyadenylated mRNA.
NAAAAAAA
>pdb|5LZX|hh Chain hh, Structure of the mammalian rescue complex with Pelota and Hbs1l assembled on a UGA stop codon.
NCAAAGTT
>pdb|5LZW|hh Chain hh, Structure of the mammalian rescue complex with Pelota and Hbs1l assembled on a truncated mRNA.
NCAAAGTT
>pdb|6GQ1|AY Chain AY, Cryo-EM reconstruction of yeast 80S ribosome in complex with mRNA, tRNA and eEF2 (GMPPCP/sordarin)
NAATTTTT
>pdb|7D0Z|A Chain A, NMR solution structures of the DNA minidumbbell formed by two CCTG repeats at pH 5
NCTGCCTG
>pdb|7D0Y|A Chain A, NMR solution structures of the DNA minidumbbell formed by two CmCTG repeats at pH 5
NNTGCNTG
>MD439631.1 JP 2019062898-A/22: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
TCTGTAAA
>MD439630.1 JP 2019062898-A/21: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
TTTACAGA
>MD439627.1 JP 2019062898-A/18: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GTTCCGGC
>MD439626.1 JP 2019062898-A/17: RATIONALLY-DESIGNED SINGLE-CHAIN MEGANUCLEASES WITH NON-PALINDROMIC RECOGNITION SEQUENCES
GCCGGAAC
>MD436031.1 JP 2019055991-A/17: METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS
NCTAAANC
>MD436025.1 JP 2019055991-A/11: METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS
NCTAACNC
>MD655914.1 JP 2019059769-A/41: INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY
GCTGGCAG
>MD655913.1 JP 2019059769-A/40: INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY
GCTGGCAG
>MD655912.1 JP 2019059769-A/39: INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY
GCTGGCAG
>MD655911.1 JP 2019059769-A/38: INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY
GCTGGCAG
>MD655910.1 JP 2019059769-A/37: INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY
GCTGGCAG
>MD655909.1 JP 2019059769-A/36: INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY
GCTGGCAG
>MD655908.1 JP 2019059769-A/35: INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY
GCTGGCAG
>MD655907.1 JP 2019059769-A/34: INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY
GCTGGCAG
>MD655906.1 JP 2019059769-A/33: INDUCED EXON INCLUSION IN SPINAL MUSCLE ATROPHY
GCTGGCAG
>pdb|6Z1A|F Chain F, Ternary complex of Staphylococcus aureus DNA gyrase with AMK12 and DNA
AGCCGTAG
>pdb|6Z1A|E Chain E, Ternary complex of Staphylococcus aureus DNA gyrase with AMK12 and DNA
AGCCGTAG
>pdb|6ZH8|C Chain C, Cryo-EM structure of DNA-PKcs:DNA
NCTAAAAA
>pdb|7CCJ|D Chain D, Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
NATGNTCC
>pdb|7CCJ|C Chain C, Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
GGATCATC
>pdb|7CCJ|F Chain F, Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
NATGNTCC
>pdb|7CCJ|E Chain E, Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
GGATCATC
>pdb|7CC9|I Chain I, Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
GGGCCGCC
>pdb|7CC9|H Chain H, Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
GGCGNCCC
>pdb|7CC9|G Chain G, Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
GGGCCGCC
>pdb|7CC9|F Chain F, Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
GGCGNCCC
>pdb|7CC9|E Chain E, Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
GGGCCGCC
>pdb|7CC9|D Chain D, Sulfur binding domain of SprMcrA complexed with phosphorothioated DNA
GGCGNCCC
>pdb|5CH0|A Chain A, Crystal structure of an A-form DNA duplex containing 5-hydroxylmethylcytidine
GNGTANAC
